



Kyung Woo Park, MD, PhD, MBA

Professor of Medicine

Department of Internal Medicine, Cardiovascular Center

Seoul National University Hospital & Seoul National University College of Medicine,
Seoul Korea

Dr Kyung Woo Park received his medical degree from Seoul National University College of Medicine. He continued his education at Seoul National University Graduate School of Medicine by earning a MS and PhD in Medical Science. He also went on to pursue an MBA at the Wharton School, University of Pennsylvania with concentration in Healthcare Management and Finance. He is board certified in Cardiovascular Medicine from the Korean Society of Cardiology and board certified in Internal Medicine from the Korean Medical Association. Dr Park is also a fellow of the American College of Cardiology and the European Society of Cardiology. He is the Chair of the International Affairs Committee and a board member of the Korean Society of Cardiology. He also holds board member positions in the Asia-Pacific Society of Cardiology Scientific Advisory Board and the Asia-Pacific Society of Interventional Cardiology. He is a member of the board of trustees of the Dongwon Educational Foundation and was a medical advisor to the Special Olympics Korea.

Clinically, Dr. Park is an interventional cardiologist and a Professor of Medicine at the Cardiovascular Center of Seoul National University Hospital in Seoul, Korea. He performs coronary intervention and structural heart disease intervention including the Mitraclip procedure and ASD/PDA/PFO closure. His primary research interest is clinical trials in the field of interventional cardiology including DES trials, and antiplatelet therapy. He was involved in the design, coordination, and management of

the HOST series of Trials (HOST-ASSURE, HOST-RP ACS, HOST-EXAM), the EXCELLENT trial, ECO-PLEASANT trial, and others. Dr. Park has published numerous articles as the first or corresponding author in top journals including the Lancet, Circulation, JACC, European Heart Journal, JAMA Cardiology, etc. regarding vascular biology, interventional cardiology, stent comparisons, antiplatelet therapy, and clopidogrel response variability. He also serves as one of the associate editors for Circulation Cardiovascular Interventions, one of the official journals of the American Heart Association and one of the deputy editors for Journal of the Asia Pacific Society of Cardiology, the official journal of the Asia Pacific Society of Cardiology. He also holds a board position on the American Heart Association Journal Equity, Diversity, and Inclusion editorial board.

Curriculum Vitae of Kyung Woo Park

(Last updated: 2024-11-10)



PERSONAL INFORMATION

Name: Kyung Woo Park, MD, PhD, MBA

Korean Medical License Number: 64790

Internal Medicine Board Certification Number: 8480

Current Address:

Department of Internal Medicine, Cardiovascular Center,
Seoul National University Hospital
101 Daehak-ro, Jongno-gu,
Seoul 03081, Korea

EDUCATION

Mar. 1992 - Feb. 1994: Seoul National University, College of Liberal Arts & Science
(Pre-medical course)

Mar. 1994 - Feb. 1998: Seoul National University College of Medicine (M.D.)

Mar. 2001 - Feb. 2003: Postgraduate School, Seoul National University (Masters of
Medical Science)

Sept. 2005 – Feb. 2008: Postgraduate School, Seoul National University (Ph.D. in
Medical Science)

Sept. 2014 – May 2016: University of Pennsylvania, the Wharton School (MBA in
Healthcare Management and Finance)

BRIEF CHRONOLOGY OF EMPLOYMENT

Mar. 1998 - Feb. 1999 Intern, Seoul National University Hospital, Seoul, Korea

Mar. 1999 - Feb. 2003 Resident (Internal Medicine), Seoul National University
Hospital, Seoul, Korea

May. 2003 – Feb. 2004 Captain (Medical Officer), 11th Infantry Division, ROK Army,
Gangwon, Korea

Feb. 2004 – April 2006 Captain (Medical Officer), Presidential Security Services
(PSS), Seoul, Korea

May. 2006 – Feb. 2008 Clinical Fellow, Division of Cardiology, Department of
Internal Medicine, Seoul National University Hospital, Seoul, Korea

Mar. 2008 – Mar. 2012 Assistant Professor, Department of Internal Medicine,

Cardiovascular Center, Seoul National University Hospital, Seoul, Korea
Apr. 2012 – Aug. 2018 Associate Professor, Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, Seoul, Korea
Jan. 2012 – Jun. 2014 Executive Director, International Healthcare Center, Seoul National University Hospital, Seoul, Korea
Jun. 2016 – May 2018 Director, Cardiac Cath Lab, Cardiovascular Center, Seoul National University Hospital, Seoul, Korea
Jun. 2016 – May 2019 Deputy Chief of Planning, Budget, and Strategy, Seoul National University Hospital, Seoul, Korea
Mar. 2019 – July 2019 Vice President and Chief of Global Operations and Business Development, Seoul National University Hospital, Seoul, Korea
Jun. 2019 – May 2021 Chief Innovation and Quality Officer, Seoul National University Hospital, Seoul, Korea
July 2021 – July 2023 President, Seoul National University Hospital Healthcare Systems Gangnam Center
Sep. 2018 – Present Professor, Department of Internal Medicine Cardiovascular Center, Seoul National University Hospital, Seoul, Korea
Jul. 2018 – Present Associate Editor, Circulation CV Interventions, American Heart Association (AHA), USA
Jan. 2022 – Present Board Member, American Heart Association Journal Diversity, Equity, Inclusion, and Accessibility Editorial Board, USA
Jan. 2024 – Present Secretary General, Organizing Committee, 2025 Asian Pacific Society of Cardiology Congress

PRESENT POSITIONS:

- Professor of Medicine, Department of Internal Medicine, Cardiovascular Center Seoul National University Hospital, Seoul Korea
- Associate Editor, Circulation Cardiovascular Intervention, American Heart Association (AHA), USA
- Board Member, American Heart Association Journal Diversity, Equity, Inclusion, and Accessibility Editorial Board, USA
- Deputy Editor, Journal of the Asia-Pacific Society of Cardiology (JAPSC)
- Secretary General, Organizing Committee, 2025 Asian Pacific Society of Cardiology Congress
- Board of Directors and Director of International Affairs, Korean Society of Cardiology (KSC), Seoul, Korea

- Board Member, Scientific Advisory Board, Asia Pacific Society of Cardiology (APSC)
- Board Member, Asia Pacific Society of Interventional Cardiology (APSIC)
- Board of Directors, Korean Society of Lipid and Atherosclerosis
- Course Advisory Committee and Scientific Committee Member, ENCORE-Seoul Meeting, Korea
- Board of Trustees, Dongwon Educational Foundation, Korea
- Board of Trustees, Foundation for Medical Innovation, Korea
- Board of Trustees, Cardiovascular Research Foundation, Korea
- Chief Medical Officer, Blockchain Labs, Seoul, Korea

PAST POSITIONS:

- President, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Korea (2021-2023)
- Chief Innovation and Quality Officer, Seoul National University Hospital, Seoul, Korea (2019-2021)
- Vice President and Chief of Global Operations and Business Development, Seoul National University Hospital (2019)
- Deputy Chief of Planning, Budget, and Strategy, Seoul National University Hospital (2016-2019)
- Director of Cardiac Catheterization Lab, Cardiovascular Center (2016-2018)
- Summer Associate, McKinsey & Co (New Jersey Office) (2015)
- Executive Director of International Healthcare Center (2012-2014)
- Deputy Director of International Healthcare Center (2010-2012)
- Assistant & Associate Professor of Medicine, Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital (2008-2012, 2012-2017)
- Non-executive Director, Member of Board of Directors, EzCaretech Inc (2021-2023)
- Medical Officer in the President's Medical Team, Presidential Security Services (2004-2006)
- Director of General Affairs, Board of Directors, Korean Society of Lipid and Atherosclerosis
- Member, General Affairs Committee, Korean Society of Cardiology
- Member, Scientific Committee, Korean Society of Cardiology,
- Member, Scientific Committee, Korean Society of Interventional Cardiology
- Aviation Medical Examiner, Consultant, Asiana Airlines
- Member, Scientific Committee, ESC (European Society of Cardiology)-Asia
- Asan Award in Medicine Review and Awards Committee, The Asan Foundation

- Medical Advisor, Special Olympics Korea
- Program Development Committee Member, Transcatheter Therapeutics 2024

LICENSE AND MEMBERSHIP

Korean Medical License (Korean Ministry of Public Health and Welfare): 1998
Board Certification in Internal Medicine (Korean Medical Association): 2003
Board Certification in Cardiovascular Medicine (Korean Society of Cardiology): 2008

ECFMG Certificate: 2006

Fellow, American College of Cardiology (FACC)
Fellow, European Society of Cardiology (FESC)
Member of Korean Medical Association
Member of Korean Society of Cardiology
Member of Korean Society of Cardiovascular Intervention

Aviation Medical Examiner (Ministry of Land, Infrastructure, and Transport)

RESEARCH INTERESTS

- [1] Clinical Trials (IIT): EXCELLENT Trial, ECO-PLEASANT Trial, HOST-ASSURE Trial, HOST-REDUCE POLYTECH Trial, HOST-EXAM Trial
- [2] QCA core lab analysis
- [3] Antiplatelet and antithrombotic agents, Platelet response variability
- [4] East Asian paradox in antithrombotic therapy: ethnic differences in relative tradeoff between thrombosis and bleeding
- [5] Data management and mass data analysis: biostatistics
- [6] Pathologic mechanism of Stent thrombosis and clinical/genetic predictors of ST
- [7] Vascular biology; atherosclerosis mechanism, implication of MDR gene in restenosis and remodeling after vascular injury
- [8] Pathogenesis of atherosclerosis and coronary artery disease
- [9] Vasospasm biology and genetic predisposition
- [10] Familial Hypercholesterolemia

AWARDS AND RECOGNITIONS

1995.08: Best Speaker Award at the Asian Medical Student's Association Annual Meeting (Hong Kong)

1999.2: Excellent Intern Commendation, Seoul National University Hospital
2001.12: Excellent Resident Commendation, Seoul National University Hospital
2005.10: Presidential Security Services Director's Commendation
2006.09: Best Presentation Award at the 32nd Annual Meeting of the Korean Society of Lipid and Atherosclerosis
2006.12: Minister's Award, Ministry of Education & Human Resources Development
2011.12: 13th Hamchoon Internal Medicine Research Award
2013.11: 23rd Wunsch Medical Award, Young Scientist Prize
2014.12: Astra Zeneca Research Award, Korean Society of Cardiology
2020.12: 22nd Hamchoon Internal Medicine Research Award
2023.06: Seoul National University Research Award, the Shim Ho Sup Award
2023.06: Seoul National University Research Award, Excellent Research Paper Award
2023.12: 27th Hamchoon Medical Research Award
2024.10: Seoul National University College of Medicine, Excellent Faculty Research Award

Publication List

[266 Papers in SCI Indexed Journals, 13 Books]

Scientific Papers:

1. Kang J, Chung J, **Park KW(corresponding author)**, Bae JW, Lee H, Hwang D, Yang HM, Han KR, Moon KW, Kim U, Rhee MY, Kim DI, Kim SY, Lee SY, Lee SU, Kim SW, Kim SY, Han JK, Shin ES, Koo BK, Kim HS. Long-Term Aspirin vs. Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity. JAMA Cardiol. 2024 Nov 27 (in press)
2. Kang J, Yun J, **Park KW(corresponding author)**, Park M, Park S, Hwang D, Han JK, Yang HM, Kang HJ, Koo BK, Angiolillo DJ, Urban P, Kim HS. Long-term outcomes of high bleeding risk patients undergoing percutaneous coronary intervention: a Korean nationwide registry. Eur Heart J. 2024 Sep 29;45(36):3721-3731. doi: 10.1093/eurheartj/ehae462.
3. Kang J, Park SH, **Park KW(corresponding author)**, Koo BK, Lee H, Han M, Hwang D, Yang HM, Chae IH, Shin WY, Oh JH, Kim YH, Park TH, Kim BS, Han JK, Shin ES, Kim HS. Clopidogrel Versus Aspirin as Chronic

Maintenance Antiplatelet Monotherapy in Patients After Percutaneous Coronary Intervention With Chronic Kidney Disease: A Post Hoc Analysis of the HOST-EXAM Trial. *J Am Heart Assoc.* 2024 Sep 17;13(18):e035269. doi: 10.1161/JAHA.124.035269. Epub 2024 Sep 9.

4. SCORE2 Asia-Pacific writing group; SCORE2 Asia-Pacific collaborators, the European Society of Cardiology and European Association of Preventive Cardiology; Cardiovascular Risk Collaboration (ESC CRC); ASEAN Federation of Cardiology (AFC); Asian-Pacific Society of Cardiology (APSC). Risk prediction of cardiovascular disease in the Asia-Pacific region: the SCORE2 Asia-Pacific model. *Eur Heart J.* 2024 Sep 1:ehae609. doi: 10.1093/eurheartj/ehae609. Online ahead of print.
5. Han M, Kang J, Kwon S, Jeon J, You SJ, Hwang D, Han JK, Yang HM, **Park KW**, Kang HJ, Koo BK, Kim HS. The Impact of Transcatheter Aortic Valve Implantation on Health Care Costs and Clinical Outcomes Based on Frailty Risk: A Nationwide Cohort Analysis. *Can J Cardiol.* 2024 Jul 31:S0828-282X(24)00584-1. doi: 10.1016/j.cjca.2024.07.025.
6. Kang J, Park S, Han M, **Park KW**, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Impact of Complete Revascularization for Acute Myocardial Infarction In Multivessel Coronary Artery Disease Patients With Diabetes Mellitus. *Korean Circ J.* 2024 Oct;54(10):603-615. doi: 10.4070/kcj.2024.0017. Epub 2024 Jun 4.
7. Kang J, Hwang D, **Park KW(co-first author)**, Han JK, Yang HM, Kang HJ, Koo BK, Lim YH, Rhew JY, Chun KJ, Lee BK, Kim S, Bae JW, Kim HS, Host Reduce Polytech Rct Trial Investigators OBOT. Durable-polymer versus biodegradable-polymer drug-eluting stents in acute coronary syndromes: three-year outcomes of the HOST REDUCE POLYTECH RCT Trial. *EuroIntervention.* 2024 Jun 17;20(12):e750-e759. doi: 10.4244/EIJ-D-23-01053
8. Han JK, Yang S, Hwang D, Park SH, Kang J, Yang HM, **Park KW**, Kang HJ, Koo BK, Cho JM, Cho J, Bang DW, Lee JH, Lee HC, Kim KJ, Chun WJ, Seo

WW, Park WJ, Park SM, Kim JW, Kim HS. Biodegradable Polymer Versus Polymer-Free Ultrathin Sirolimus-Eluting Stents: Analysis of the Stent Arm Registry From the HOST-IDEA Randomized Trial. *Circ Cardiovasc Interv.* 2024 Jul;17(7):e013585. doi: 10.1161/CIRCINTERVENTIONS.123.013585. Epub 2024 May 24.

9. Park S, Hwang D, Kang J, Han JK, Yang HM, **Park KW**, Kang HJ, Koo BK, Cho JM, Cho BR, Ahn SG, Kang SM, Sung JH, Kim U, Lee N, Kim HS. Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients with Dyslipidemia and Hypertension: A Multicenter Randomized Clinical Trial. *Curr Ther Res Clin Exp.* 2024 Feb 1;100:100735. doi: 10.1016/j.curtheres.2024.100735. eCollection 2024. PMID: 38380420
10. Kang J, Lee KS, Lee HS, Lee H, Ahn H, Han JK, Yang HM, **Park KW**, Lee HY, Kang HJ, Koo BK, Kim HS, Cho HJ. Differential effect of left ventricular unloading according to the aetiology of cardiogenic shock. *ESC Heart Fail.* 2023 Nov 27. doi: 10.1002/ehf2.14584. Online ahead of print. PMID: 38012086
11. Yang S, Kang J, **Park KW (corresponding author)**, Hur SH, Lee NH, Hwang D, Yang HM, Ahn HS, Cha KS, Jo SH, Ryu JK, Suh IW, Choi HH, Woo SI, Han JK, Shin ES, Koo BK, Kim HS. Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks. *J Am Coll Cardiol.* 2023 Oct 17;82(16):1565-1578. doi: 10.1016/j.jacc.2023.07.031. PMID: 37821166 Clinical Trial.
12. Lee K, Kang J, **Park KW (corresponding author)**, Park TH, Kim BS, Lim SW, Cho YH, Jeon DW, Kim SH, Yang HM, Kang HJ, Han JK, Shin ES, Koo BK, Kim HS. Impact of Age on Antiplatelet Monotherapy in the Chronic Maintenance Period After PCI: A Post-hoc Analysis from the HOST-EXAM Extended Study. *Can J Cardiol.* 2023 Sep 22:S0828-282X(23)01736-1. doi: 10.1016/j.cjca.2023.09.021. Online ahead of print. PMID: 37742741
13. Bruno F, Kang J, Elia E, Han JK, De Filippo O, Yang HM, Gallone G, **Park**

- KW**, De Luca L, Kang HJ, Quadri G, Gwon HC, Chun WJ, Giannino G, Hur SH, Han SH, Truffa A, Bin Song Y, Cortese B, Choi KH, Chieffo A, Hong SJ, Di Pietro G, Doh JH, Wanha W, Nam CW, Kim HS, Mattesini A, de De Ferrari GM, Koo BK, D'Ascenzo F. Impact of diabetes on long-term outcomes of bifurcation percutaneous coronary intervention. An analysis from the BIFURCAT registry. *Catheter Cardiovasc Interv.* 2023 Sep 5. doi: 10.1002/ccd.30802. Online ahead of print.
14. Kang J, **Park KW (corresponding author)**, Kim HS. Comparison of standard ticagrelor and prasugrel therapies based on previous trials. *Eur Heart J.* 2023 Aug 22;44(32):3102-3103. doi: 10.1093/eurheartj/ehad433.
 15. Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen AR, Zhao Q, Woodward M, Chiarito M, McFadden EP, **Park KW**, Kastrati A, Seljeflot I, Zhu Y, Windecker S, Kang J, Schunkert H, Arnesen H, Bhatt DL, Steg PG, Calabrò P, Pocock S, Mehran R, Valgimigli M; PANTHER Collaboration. P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. *J Am Coll Cardiol.* 2023 Jul 11;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051.PMID: 37407118
 16. Kang J, Chung J, **Park KW (corresponding author)**, Lee H, Hwang D, Yang HM, Han JK, Shin ES, Koo BK, Kim HS. Clopidogrel vs Aspirin in the Chronic Maintenance Period for Patients With Acute Coronary Syndrome. *JACC Cardiovasc Interv.* 2023 Jun 26;16(12):1553-1555. doi: 10.1016/j.jcin.2023.03.004. PMID: 37380245
 17. Park CS, Yang HM, Han K, Lee HS, Kang J, Han JK, **Park KW**, Kang HJ, Koo BK, Kim HS. J-shaped association between LDL cholesterol and cardiovascular events: A longitudinal primary prevention cohort of over 2.4 million people nationwide. *J Adv Res.* 2023 May 22:S2090-1232(23)00141-8. doi: 10.1016/j.jare.2023.05.003. Online ahead of print. PMID: 37225014
 18. Hwang D, Kim HL, Koo BK, Rhee TM, Yang DW, Seo Y, Byun J, Kang J, Han JK, **Park KW**, Shin ES, Rha SW, Bae JW, Mamas MA, Cohen DJ, Lee TJ,

- Kim HS; HOST-EXAM Investigators. Cost-Effectiveness of Clopidogrel vs Aspirin Monotherapy After Percutaneous Coronary Intervention: Results From the HOST-EXAM Study. *JACC Asia*. 2023 Mar 14;3(2):198-207. doi: 10.1016/j.jacasi.2022.12.007. eCollection 2023 Apr. PMID: 37181388
19. Rhee TM, Bae JW, **Park KW (corresponding author)**, Rha SW, Kang J, Lee H, Yang HM, Kwak SH, Chae IH, Shin WY, Kim DK, Oh JH, Jeong MH, Kim YH, Lee NH, Hur SH, Yoon J, Han JK, Shin ES, Koo BK, Kim HS; HOST-EXAM Investigators. Aspirin vs Clopidogrel for Long-term Maintenance After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the HOST-EXAM Trial. *JAMA Cardiol*. 2023 Jun 1;8(6):535-544. doi: 10.1001/jamacardio.2023.0592. PMID: 37043192
 20. Shin ES, Jun EJ, Kim B, Won KB, Koo BK, Kang J, **Park KW**, Rhee TM, Yang HM, Han JK, Kim HS; HOST-EXAM Investigators. Association of Clinical Outcomes With Sex in Patients Receiving Chronic Maintenance Antiplatelet Monotherapy After Percutaneous Coronary Intervention: A Post Hoc Gender Analysis of the HOST-EXAM Study. *J Am Heart Assoc*. 2023 Apr 18;12(8):e026770. doi: 10.1161/JAHA.122.026770. Epub 2023 Apr 12. PMID: 37042284
 21. Kang J, Rizas KD, **Park KW (corresponding author)**, Chung J, van den Broek W, Claassens DMF, Choo EH, Aradi D, Massberg S, Hwang D, Han JK, Yang HM, Kang HJ, Chang K, Ten Berg JM, Sibbing D, Koo BK, Kim HS. Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis. *Eur Heart J*. 2023 Apr 17;44(15):1360-1370. doi: 10.1093/eurheartj/ehac829. PMID: 36883613
 22. Yun JP, Kang J, **Park KW (corresponding author)**, Park K, Hwang D, Han JK, Yang HM, Kang HJ, Koo BK, Chae IH, Moon KW, Park HW, Won KB, Jeon DW, Han KR, Choi SW, Ryu JK, Jeong MH, Kim HS. Prasugrel-Based De-Escalation in Patients With Acute Coronary Syndrome According to Renal Function. *JACC Asia*. 2023 Jan 10;3(1):51-61. doi: 10.1016/j.jacasi.2022.09.013. eCollection 2023 Feb. PMID: 36873753

23. Han JK, Hwang D, Yang S, Park SH, Kang J, Yang HM, **Park KW**, Kang HJ, Koo BK, Hur SH, Kim W, Kim SY, Park SH, Han SH, Kim SH, Shin S, Kim YH, Park K, Lee N, Lee SJ, Kim JW, Kim HS. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial. *Circulation*. 2023 May 2;147(18):1358-1368. PMID: 36871230
24. Yang HM, Lee JE, Kim JY, You J, Kim J, Lee HS, Yoo HM, Kong MG, Han JK, Cho HJ, **Park KW**, Kang HJ, Koo BK, Park YB, Kim HS. Identification of cell-biologic mechanisms of coronary artery spasm and its ex vivo diagnosis using peripheral blood-derived iPSCs. *Biomater Res*. 2023 Feb 18;27(1):16. doi: 10.1186/s40824-023-00345-2. PMID: 36803875
25. Lee KS, Park KH, **Park KW (corresponding author)**, Rha SW, Hwang D, Kang J, Han JK, Yang HM, Kang HJ, Koo BK, Lee NH, Rhew JY, Chun KJ, Lim YH, Bong JM, Bae JW, Lee BK, Kim SY, Shin WY, Lim HS, Park K, Kim HS. Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial. *Eur Heart J Cardiovasc Pharmacother*. 2023 Apr 10;9(3):262-270. doi: 10.1093/ehjcvp/pvad008. PMID: 36715152
26. Kang J, Han JK, Yang HM, **Park KW**, Kang HJ, Koo BK, Choo EH, Lee JY, Park SD, Lim YH, Kim HM, Heo JH, Kim HS. Real-world evidence of switching P2Y12 receptor-inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry. *BMC Cardiovasc Disord*. 2023 Jan 9;23(1):6. doi: 10.1186/s12872-022-03034-5. PMID: 36624388
27. Kang J, Bruno F, Rhee TM, De Luca L, Han JK, de Filippo O, Yang HM, Mattesini A, **Park KW**, Truffa A, Kim HS, Wojciech W, Gwon HC, Gili S, Chun WJ, Helft G, Hur SH, Cortese B, Han SH, Escaned J, Song YB, Chieffo A, Choi KH, Gallone G, Doh JH, De Ferrari G, Hong SJ, Quadri G, Nam CW, Koo BK, D'Ascenzo F. Impact of Clinical and Lesion Features on Outcomes

After Percutaneous Coronary Intervention in Bifurcation Lesions. *JACC Asia*. 2022 Sep 20;2(5):607-618. doi: 10.1016/j.jacasi.2022.05.003. eCollection 2022 Oct. PMID: 36518719

28. Palmerini T, Bruno AG, Gasparini M, Rizzello G, Kim HS, Kang J, **Park KW**, Hahn JY, Song YB, Gwon HC, Choo EH, Park MW, Kim CJ, Chang K, Cuisset T, Taglieri N, Kim BK, Jang Y, Nardi E, Saia F, Orzalkiewicz M, Chietera F, Ghetti G, Galiè N, Stone GW. Reduced Mortality With Antiplatelet Therapy Deescalation After Percutaneous Coronary Intervention in Acute Coronary Syndromes: A Meta-Analysis. *Circ Cardiovasc Interv*. 2022 Nov;15(11):906-914. doi: 10.1161/CIRCINTERVENTIONS.122.012245. Epub 2022 Nov 15. PMID: 36378738
29. Kang J, **Park KW (co-first author)**, Lee H, Hwang D, Yang HM, Rha SW, Bae JW, Lee NH, Hur SH, Han JK, Shin ES, Koo BK, Kim HS. Aspirin vs. Clopidogrel for Chronic Maintenance Monotherapy after Percutaneous Coronary Intervention: the HOST-EXAM Extended Study. *Circulation*. 2023 Jan 10;147(2):108-117. doi: 10.1161/CIRCULATIONAHA.122.062770. Epub 2022 Nov 7.
30. Won KB, Shin ES, Kang J, Yang HM, **Park KW**, Han KR, Moon KW, Oh SK, Kim U, Rhee MY, Kim DI, Kim SY, Lee SY, Han JK, Koo BK, Kim HS. Body Mass Index and Major Adverse Events During Chronic Antiplatelet Monotherapy After Percutaneous Coronary Intervention With Drug-Eluting Stents - Results From the HOST-EXAM Trial. *Circ J*. 2022 Sep 16. doi: 10.1253/circj.CJ-22-0344. Online ahead of print.
31. Lee SR, Jung JH, Choi EK, Lee SW, Kwon S, Park JS, Kang J, Han KD, **Park KW**, Oh S, Lip GYH. Net clinical benefit of antithrombotic therapy for atrial fibrillation patients with stable coronary artery disease. *Front Cardiovasc Med*. 2022 Aug 22;9:991293. doi: 10.3389/fcvm.2022.991293. eCollection 2022. PMID: 36072876
32. Park CS, Yang HM, Kang J, Han JK, **Park KW**, Kang HJ, Koo BK, Seung KB,

- Cha KS, Seong IW, Rha SW, Jeong MH, Kim HS. Long-term use of renin-angiotensin-system inhibitors after acute myocardial infarction is not associated with survival benefits: Analysis of data from the Korean acute myocardial infarction registry-national institutes of health registry. *Front Cardiovasc Med*. 2022 Aug 31;9:994419. doi: 10.3389/fcvm.2022.994419. eCollection 2022.
33. Hwang D, Lim HS, **Park KW (corresponding author)**, Shin WY, Kang J, Han JK, Yang HM, Kang HJ, Koo BK, Cho YK, Hong SJ, Kim S, Jo SH, Kim YH, Kim W, Lee SY, Oh SK, Kim DB, Kim HS. Durable polymer versus biodegradable polymer drug-eluting stents in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: a post hoc analysis of the HOST-REDUCE-POLYTECH-ACS trial. *EuroIntervention*. 2022 Aug 24;EIJ-D-22-00372. doi: 10.4244/EIJ-D-22-00372. Online ahead of print. PMID: 36000257
34. Park J, Han JK, Kang J, Chae IH, Lee SY, Choi YJ, Rhew JY, Rha SW, Shin ES, Woo SI, Lee HC, Chun KJ, Kim D, Jeong JO, Bae JW, Yang HM, **Park KW**, Kang HJ, Koo BK, Kim HS. The Clinical Impact of β -Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention. *Korean Circ J*. 2022 Jul;52(7):544-555. doi: 10.4070/kcj.2021.0395. Epub 2022 Apr 4.
35. Hwang D, Park J, Yang HM, Yang S, Kang J, Han JK, **Park KW**, Kang HJ, Koo BK, Kim HS. Angiographic complete revascularization versus incomplete revascularization in patients with diabetes mellitus. *Cardiovasc Diabetol*. 2022 Apr 19;21(1):56. doi: 10.1186/s12933-022-01488-7.
36. Gallone G, Kang J, Bruno F, Han JK, De Filippo O, Yang HM, Doronzo M, **Park KW**, Mittone G, Kang HJ, Parma R, Gwon HC, Cerrato E, Chun WJ, Smolka G, Hur SH, Helft G, Han SH, Muscoli S, Song YB, Figini F, Choi KH, Boccuzzi G, Hong SJ, Trabattoni D, Nam CW, Giammaria M, Kim HS, Conrotto F, Escaned J, Di Mario C, D'Ascenzo F, Koo BK, de Ferrari GM. Impact of Left Ventricular Ejection Fraction on Procedural and Long-Term Outcomes of Bifurcation Percutaneous Coronary Intervention. *Am J Cardiol*.

2022 Jun 1;172:18-25. doi: 10.1016/j.amjcard.2022.02.015. Epub 2022 Mar 30.

37. Hwang D, Lim YH, **Park KW (corresponding author)**, Chun KJ, Han JK, Yang HM, Kang HJ, Koo BK, Kang J, Cho YK, Hong SJ, Kim S, Jo SH, Kim YH, Kim W, Lee SY, Kim YD, Oh SK, Lee JH, Kim HS; HOST-RP-ACS investigators. Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the HOST-REDUCE-POLYTECH-ACS Trial. *JAMA Cardiol.* 2022 Mar 9. doi: 10.1001/jamacardio.2022.0052.
38. Ahmed TAN, Ki YJ, Choi YJ, El-Naggar HM, Kang J, Han JK, Yang HM, **Park KW**, Kang HJ, Koo BK, Kim HS. Impact of Systemic Inflammatory Response Syndrome on Clinical, Echocardiographic, and Computed Tomographic Outcomes Among Patients Undergoing Transcatheter Aortic Valve Implantation. *Front Cardiovasc Med.* 2022 Feb 9;8:746774. doi: 10.3389/fcvm.2021.746774. eCollection 2021.
39. Park J, Jung JH, Choi EK, Lee SW, Kwon S, Lee SR, Kang J, Han KD, **Park KW**, Oh S, Lip GYH. Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. *PLoS One.* 2022 Feb 25;17(2):e0264538. doi: 10.1371/journal.pone.0264538. eCollection 2022. PMID: 35213632
40. Ki YJ, Lee BK, **Park KW (corresponding author)**, Bae JW, Hwang D, Kang J, Han JK, Yang HM, Kang HJ, Koo BK, Kim DB, Chae IH, Moon KW, Park HW, Won KB, Jeon DW, Han KR, Choi SW, Ryu JK, Jeong MH, Cha KS, Kim HS; HOST-RP-ACS investigators. Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI. *Korean Circ J.* 2021 Dec 21. doi: 10.4070/kcj.2021.0293. Online ahead of print.
41. Palmerini T, Bruno AG, Redfors B, Valgimigli M, Taglieri N, Feres F, Abizaid A, Costa R, Gilard M, Morice MC, Hong MK, Kim BK, Jang Y, Kim HS, **Park**

- KW**, Colombo A, Chieffo A, Nakamura M, Kotinkaduwa LN, Nardi E, Saia F, Gasparini M, Rizzello G, Weisz G, Kirtane AJ, Mehran R, Witzenbichler B, Galiè N, Stone GW. Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk. *J Am Coll Cardiol*. 2021 Nov 16;78(20):1968-1986. doi: 10.1016/j.jacc.2021.08.070.
42. Kang J, Koo BK, **Park KW**, Shin ES, Kim HS. Aspirin versus clopidogrel after percutaneous coronary intervention - Authors' reply. *Lancet*. 2021 Nov 6;398(10312):1685-1686. doi: 10.1016/S0140-6736(21)02016-X.
43. Cha MJ, Oh GC, Ki YJ, Chang M, Kang J, Han JK, Yang HM, **Park KW**, Kang HJ, Koo BK, Oh S, Kim HS. Time Course and Risk Factors of New-Onset Complete Atrioventricular Block After Transcatheter Aortic Valve Implantation. *Int Heart J*. 2021 Sep 30;62(5):988-996. doi: 10.1536/ihj.20-824. Epub 2021 Sep 17.
44. De Filippo O, Kang J, Bruno F, Han JK, Saglietto A, Yang HM, Patti G, **Park KW**, Parma R, Kim HS, De Luca L, Gwon HC, Iannaccone M, Chun WJ, Smolka G, Hur SH, Cerrato E, Han SH, di Mario C, Song YB, Escaned J, Choi KH, Helft G, Doh JH, Truffa Giachet A, Hong SJ, Muscoli S, Nam CW, Gallone G, Capodanno D, Trabattoni D, Imori Y, Dusi V, Cortese B, Montefusco A, Conrotto F, Colonnelli I, Sheiban I, de Ferrari GM, Koo BK, D'Ascenzo F. Benefit of Extended Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients Treated with Drug Eluting Stents for Coronary Bifurcation Lesions (from the BIFURCAT Registry). *Am J Cardiol*. 2021 Oct 1;156:16-23. doi: 10.1016/j.amjcard.2021.07.005. Epub 2021 Aug 2.
45. Seo KW, Yang HM, Yoon J, Kim HS, Chang K, Lim HS, Choi BJ, Choi SY, Yoon MH, Lee SH, Ahn SG, Youn YJ, Lee JW, Koo BK, **Park KW**, Yang HM, Han JK, Chung WS, Park HJ, Hwang BH, Choo EH, Oh GC, Tahk SJ. Five-year clinical outcomes of the first Korean-made sirolimus-eluting coronary stent with abluminal biodegradable polymer. *Medicine (Baltimore)*. 2021 May 14;100(19):e25765. doi: 10.1097/MD.00000000000025765.

46. Kang J, Han JK, Yang HM, **Park KW**, Kang HJ, Gwon HC, Chun WJ, Hur SH, Han SH, Rha SW, Chae IH, Jeong JO, Heo JH, Yoon J, Lim DS, Park JS, Hong MK, Doh JH, Cha KS, Kim DI, Lee SY, Chang K, Hwang BH, Choi SY, Jeong MH, Song YB, Choi KH, Hong SJ, Nam CW, Koo BK, Kim HS. Comparison of 2-Stenting Strategies Depending on Sequence or Technique for Bifurcation Lesions in the Second-Generation Drug-Eluting Stent Era - Analysis From the COBIS (Coronary Bifurcation Stenting) III Registry. *Circ J.* 2021 Oct 25;85(11):1944-1955. doi: 10.1253/circj.CJ-20-0999. Epub 2021 Jun 2.
47. Koo BK, Kang J, **Park KW (co-first author)**, Rhee TM, Yang HM, Won KB, Rha SW, Bae JW, Lee NH, Hur SH, Yoon J, Park TH, Kim BS, Lim SW, Cho YH, Jeon DW, Kim SH, Han JK, Shin ES, Kim HS on behalf of the HOST-EXAM investigators. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. *Lancet* 2021 May 16. doi.org/10.1016/S0140-6736(21)01063-1
48. Lee HS, **Park KW (corresponding author)**, Kang J, Han JK, Kim HS. De-escalation of prasugrel results in higher percentage of patients within optimal range of platelet reactivity. *Thromb Haemost.* 2021 Apr 30. doi: 10.1055/a-1496-7987. Online ahead of print.
49. Park J, Jung JH, Choi EK, Lee SW, Kwon S, Lee SR, Kang J, Han KD, **Park KW**, Oh S, Lip GYH. Longitudinal Patterns in Antithrombotic Therapy in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention in the Non-Vitamin K Oral Anticoagulant Era: A Nationwide Population-Based Study. *J Clin Med.* 2021 Apr 4;10(7):1505. doi: 10.3390/jcm10071505. PMID: 33916604
50. Kwon S, Jung JH, Choi EK, Lee SW, Park J, Lee SR, Kang J, Han K, **Park KW**, Oh S, Lip GYH. Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. *Korean Circ J.* 2021 May;51(5):409-422. doi: 10.4070/kcj.2020.0407. Epub 2021 Jan

25. PMID: 33764010

51. Park CS, Yang HM, Ki YJ, Kang J, Han JK, **Park KW**, Kang HJ, Koo BK, Kim CJ, Cho MC, Kim YJ, Chae SC, Jeong MH, Kim HS; KAMIR-NIH Registry. Left Ventricular Ejection Fraction 1 Year After Acute Myocardial Infarction Identifies the Benefits of the Long-Term Use of β -Blockers: Analysis of Data From the KAMIR-NIH Registry. *Circ Cardiovasc Interv.* 2021 Apr;14(4):e010159. doi: 10.1161/CIRCINTERVENTIONS.120.010159. Epub 2021 Apr 20.
52. Kim M, **Park KW (corresponding author)**, Lee HS, Ki YJ, Kang J, Kim CH, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. The validation of the dual antiplatelet therapy score in East Asians receiving percutaneous coronary intervention with exclusively second generation drug-eluting stents. *Catheter Cardiovasc Interv.* 2021 Apr 5. doi: 10.1002/ccd.29682. Online ahead of print.
53. Shin ES, Jun EJ, Han JK, Kong MG, Kang J, Zheng C, Garg S, Choi YJ, Bae JW, Chun KJ, Kim DI, Rha SW, Lee SY, Rhew JY, Woo SI, Lee HC, Jeong JO, Yang HM, **Park KW**, Kang HJ, Koo BK, Chae IH, Kim HS. Sex-related impact on clinical outcomes of patients treated with drug-eluting stents according to clinical presentation: Patient-level pooled analysis from the GRAND-DES registry. *Cardiol J.* 2021 Feb 26. doi: 10.5603/CJ.a2021.0008. Online ahead of print.
54. Kang J, **Park KW (corresponding author)**, Lee HS, Zheng C, Rhee TM, Ki YJ, Chang M, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Relative impact of clinical risk versus procedural risk on clinical outcomes after percutaneous coronary intervention. *Circ Cardiovasc Interv.* 2021 Feb;14(2):e009642. doi: 10.1161/CIRCINTERVENTIONS.120.009642. Epub 2021 Feb 5.
55. Lee HS, Kang J, **Park KW** (corresponding author), Ki YJ, Chang M, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Procedural optimization of drug-coated balloons in the treatment of coronary artery disease. *Catheter Cardiovasc Interv.* 2021 Jan 25. doi: 10.1002/ccd.29492. Online ahead of print.

56. Oh GC, **Park KW** (corresponding author), Kang J, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Association of Side-Branch Treatment and Patient Factors in Left Anterior Descending Artery True Bifurcation Lesions: Analysis from the GRAND-DES Pooled Registry. *J Interv Cardiol.* 2020 Dec 27;2020:8858642. doi: 10.1155/2020/8858642. eCollection 2020.
57. Lee MS, Kang J, **Park KW (corresponding author)**, Cho H, Lee HS, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Percutaneous treatment of unprotected left main disease with thin strut durable polymer or early-generation thicker strutted and coated bioabsorbable polymer drug-eluting stents in a large-scale registry. *Cardiovasc Revasc Med.* 2021 Nov;32:43-49. doi: 10.1016/j.carrev.2020.12.034. Epub 2020 Dec 31.
58. Ki YJ, Kang J, Lee HS, Chang M, Han JK, Yang HM, **Park KW**, Kang HJ, Koo BK, Kim HS. Optimal Oversizing Index Depending on Valve Type and Leakage-Proof Function for Preventing Paravalvular Leakage after Transcatheter Aortic Valve Implantation. *J Clin Med.* 2020 Dec 4;9(12):3936. doi: 10.3390/jcm9123936.
59. Kang J, Yun JP, Ki YJ, Lee HS, Han JK, Yang HM, **Park KW**, Kang HJ, Koo BK, Kim HS. A New Hemodynamic Index Predicting Paravalvular Regurgitation After TAVR: Dicrotic AR Index. *JACC Cardiovasc Interv.* 2020 Nov 23;13(22):2711-2713. doi: 10.1016/j.jcin.2020.07.029.
60. Kim HS, Kang J, Hwang D, Han JK, Yang HM, Kang HJ, Koo BK, Kim SY, Park KH, Rha SW, Shin WY, Lim HS, Park K, **Park KW (corresponding author)**; HOST-REDUCE-POLYTECH-ACS investigators. Durable Polymer versus Biodegradable Polymer drug-eluting stents after percutaneous coronary intervention in patients with acute coronary syndrome: the HOST-REDUCE-POLYTECH-ACS Trial. *Circulation.* 2021 Mar 16;143(11):1081-1091. doi: 10.1161/CIRCULATIONAHA.120.051700. Epub 2020 Nov 18.
61. Park J, Choi EK, Han KD, Kim B, Choi YJ, Lee SR, Kang J, Cha MJ, **Park KW**, Oh S, Lip GYH. Outcomes in relation to antithrombotic therapy among

- patients with atrial fibrillation after percutaneous coronary intervention. *PLoS One*. 2020 Oct 15;15(10):e0240161. doi: 10.1371/journal.pone.0240161. eCollection 2020. PMID: 33057407
62. Park J, Han JK, Kang J, Chae IH, Lee SY, Choi YJ, Rhew JY, Rha SW, Shin ES, Woo SI, Lee HC, Chun KJ, Kim DI, Jeong JO, Bae JW, Yang HM, **Park KW**, Kang HJ, Koo BK, Kim HS. Optimal Dose and Type of β -blockers in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. *Am J Cardiol*. 2020 Sep 28:S0002-9149(20)31019-5. doi: 10.1016/j.amjcard.2020.09.044. Online ahead of print.
63. Lee HS, **Park KW** (corresponding author), Kang J, Ki YJ, Chang M, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Sarcopenia Index as a Predictor of Clinical Outcomes in Older Patients with Coronary Artery Disease. *J Clin Med*. 2020 Sep 27;9(10):3121. doi: 10.3390/jcm9103121.
64. Kim HS, Kang J, Hwang D, Han JK, Yang HM, Kang HJ, Koo BK, Rhew JY, Chun KJ, Lim YH, Bong JM, Bae JW, Lee BK, **Park KW (corresponding author)**; HOST-REDUCE-POLYTECH-ACS investigators. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. *Lancet*. 2020 Oct 10;396(10257):1079-1089. doi: 10.1016/S0140-6736(20)31791-8. Epub 2020 Aug 31.
65. Kim CH, Rhee TM, **Park KW (corresponding author)**, Park CS, Kang J, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Association between low muscle mass and prognosis of coronary artery disease patients undergoing percutaneous coronary intervention. *J Am Heart Assoc*. 2020 Nov. In Press.
66. Park J, Han JK, Chang M, Ki YJ, Kang J, Yang HM, Cho HJ, **Park KW**, Kang HJ, Koo BK, Kim HS. Impact of Intensive Glucose Control in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: 3-Year Clinical Outcomes. *J Clin Med*. 2020 Aug 1;9(8):E2464. doi:

10.3390/jcm9082464.

67. Ki YJ, Jung JH, Han JK, Hong S, Cho JH, Gwon HC, Lee SY, Rhew JY, Chae JK, Chae IH, Yang HM, **Park KW**, Kang HJ, Koo BK, Kim HS. Clinical Implications of Bifurcation Angles in Left Main Bifurcation Intervention Using a Two-Stent Technique. *J Interv Cardiol.* 2020 Jul 11;2020:2475930. doi: 10.1155/2020/2475930. eCollection 2020.
68. Cho H, Kang J, Kim HS, **Park KW (corresponding author)**. Ethnic Differences in Oral Antithrombotic Therapy. *Korean Circ J.* 2020 Aug;50(8):645-657. doi: 10.4070/kcj.2020.0098.
69. Chung J, Han JK, Yang HM, **Park KW**, Kang HJ, Koo BK, Jeong MH, Kim HS; investigators for Korea Acute Myocardial Infarction Registry (KAMIR). Long-term efficacy of vasodilating β -blocker in patients with acute myocardial infarction: nationwide multicenter prospective registry. *Korean J Intern Med.* 2020 Jul 3. doi: 10.3904/kjim.2020.135. Online ahead of print.
70. Jang JY, Jung HW, Lee BK, Shin DH, Kim JS, Hong SJ, Ahn CM, Kim BK, Ko YG, Choi D, Hong MK, **Park KW**, Gwon HC, Kim HS, Kwon HM, Jang Y. Impact of PRECISE-DAPT and DAPT Scores on Dual Antiplatelet Therapy Duration After 2nd Generation Drug-Eluting Stent Implantation. *Cardiovasc Drugs Ther.* 2020 Jun 25. doi: 10.1007/s10557-020-07008-7. Online ahead of print.
71. Zheng C, Kang J, Yang HM, Han JK, **Park KW**, Kang HJ, Koo BK, Kim HS. Safety and Efficacy of Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Myocardial Infarction in the Presence of Intracoronary Thrombus: An Analysis From the Grand Drug-eluting Stent Registry. *Clin Ther.* 2020 May;42(5):954-958.e6. doi: 10.1016/j.clinthera.2020.02.022. Epub 2020 Mar 26.
72. Ki YJ, **Park KW (corresponding author)**, Kang J, Kim CH, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry. *J Interv Cardiol.* 2020 Feb 26;2020:3872704. doi:

10.1155/2020/3872704. eCollection 2020.

73. Yun D, Choi Y, Lee SP, **Park KW**, Koo BK, Kim HS, Kim DK, Joo KW, Kim YS, Han SS. Blood Pressure and Renal Progression in Patients Undergoing Percutaneous Coronary Intervention. *Am J Hypertens*. 2020 Jul 18;33(7):676-684. doi: 10.1093/ajh/hpaa046.
74. Ki YJ, Kang J, Park J, Han JK, Yang HM, **Park KW (corresponding author)**, Kang HJ, Koo BK, Kim HS. Efficacy and Safety of Long-Term and Short-Term Dual Antiplatelet Therapy: A Meta-Analysis of Comparison between Asians and Non-Asians. *J Clin Med*. 2020 Feb 28;9(3):652. doi: 10.3390/jcm9030652.
75. Kang J, Zheng C, **Park KW (corresponding author)**, Park J, Rhee T, Lee HS, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Complete Revascularization of Multivessel Coronary Artery Disease Does Not Improve Clinical Outcome in ST-Segment Elevation Myocardial Infarction Patients with Reduced Left Ventricular Ejection Fraction. *J Clin Med*. 2020 Jan 15;9(1). pii: E232. doi: 10.3390/jcm9010232.
76. Jang JY, Lee BK, Kim JS, Shin DH, Hong SJ, Ahn CM, Kim BK, Ko YG, Choi D, Hong MK, **Park KW**, Gwon HC, Kim HS, Kwon HM, Jang Y. Efficacy and Safety of Guideline-Recommended Risk Score-Directed Dual Antiplatelet Therapy After 2nd-Generation Drug-Eluting Stents. *Circ J*. 2020 Jan 24;84(2):161-168. doi: 10.1253/circj.CJ-19-0667. Epub 2019 Dec 13.
77. Lee JM, Choi KH, Koo BK, Zhang J, Han JK, Yang HM, **Park KW**, Song YB, Hahn JY, Choi SH, Gwon HC, Kim HS. Intravascular ultrasound or optical coherence tomography-defined anatomic severity and hemodynamic severity assessed by coronary physiologic indices. *Rev Esp Cardiol (Engl Ed)*. 2020 Oct;73(10):812-821. doi: 10.1016/j.rec.2019.11.001. Epub 2019 Dec 4. PMID: 31812517
78. Lee MS, Shlofmitz R, Mahmud E, **Park KW**, Rha SW, Gaborro A, Wang J, Zhao W, Sudhir K. Four-Year Outcomes of Multivessel Percutaneous Coronary

Intervention With Xience V Everolimus-Eluting Stents. *J Invasive Cardiol.* 2019 Sep;31(9):240-246. PMID: 31478889

79. Zheng C, Kang J, **Park KW (corresponding author)**, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. The Predictors of Target Lesion Revascularization and Rate of In-Stent Restenosis in the Second-Generation Drug-Eluting Stent Era. *J Interv Cardiol.* 2019 Jul 1;2019:3270132. doi: 10.1155/2019/3270132. eCollection 2019. PMID: 31772522
80. Kang J, Han JK, Kang DY, Zheng C, Yang HM, **Park KW**, Kang HJ, Koo BK, Kim HS. SYNTAX Score and SYNTAX Score II Can Predict the Clinical Outcomes of Patients with Left Main and/or 3-Vessel Disease Undergoing Percutaneous Coronary Intervention in the Contemporary Cobalt-Chromium Everolimus-Eluting Stent Era. *Korean Circ J.* 2020 Jan;50(1):22-34. doi: 10.4070/kcj.2019.0097. Epub 2019 Sep 30. PMID: 31642213
81. Kong MG, Han JK, Kang JH, Zheng C, Yang HM, **Park KW**, Kang HJ, Koo BK, Chae IH, Kim HS; Collaborators. Clinical outcomes of long stenting in the drug-eluting stent era: patient-level pooled analysis from the GRAND-DES registry. *EuroIntervention.* 2021 Mar 19;16(16):1318-1325. doi: 10.4244/EIJ-D-19-00296. PMID: 31543496
82. Kim CH, **Park KW (corresponding author)**, Kang J, Park BE, Cha KS, Rhew JY, Jeon HK, Shin ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW, Kwon HM, Hur SH, Ryu JK, Lee BR, Park YW, Chae IH, Kim HS; HOST-ASSURE Investigators. Long-Term Comparison of Platinum Chromium Everolimus-Eluting Stent vs. Cobalt Chromium Zotarolimus-Eluting Stent - 3-Year Outcomes From the HOST-ASSURE Randomized Clinical Trial. *Circ J.* 2019 Jun 25;83(7):1489-1497. doi: 10.1253/circj.CJ-18-1303. Epub 2019 May 31.
83. Park J, Choi EK, Han KD, Choi YJ, Lee SR, Cha MJ, Kang J, **Park KW**, Oh S, Lip GYH. Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention During 2-Year Follow-Up, from a

- Nationwide Population Study. *Am J Cardiol.* 2019 Jun 15;123(12):1921-1926. doi: 10.1016/j.amjcard.2019.03.024. Epub 2019 Mar 16. PMID: 30967291
84. Kang J, **Park KW (corresponding author)**, Ki YJ, Park J, Rhee T, Kim CH, Han JK, Yang HM, Kang HJ, Koo BK, Nakamura M, Hamasaki T, Yokoi H, Cohen D, Kim HS. Development and Validation of an Ischemic and Bleeding Risk Evaluation Tool in East Asian Patients Receiving Percutaneous Coronary Intervention. *Thromb Haemost.* 2019 May 12. doi: 10.1055/s-0039-1688792. [Epub ahead of print]
85. Rhee TM, **Park KW**, Kim HS. Reply: Duration of Dual-Antiplatelet Therapy After Left Main Stenting: Progressive Steps Towards the Correct Answer. *JACC Cardiovasc Interv.* 2019 Apr 8;12(7):690-691. doi: 10.1016/j.jcin.2019.01.238. PMID: 30947944
86. Kang J, **Park KW (corresponding author)**, Palmerini T, Stone GW, Lee MS, Colombo A, Chieffo A, Feres F, Abizaid A, Bhatt DL, Valgimigli M, Hong MK, Jang Y, Gilard M, Morice MC, Park DW, Park SJ, Jeong YH, Park J, Koo BK, Kim HS. Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs. *Thromb Haemost.* 2019 Jan;119(1):149-162.
87. Park J, Choi EK, Han KD, Choi YJ, Lee E, Choe W, Lee SR, Cha MJ, Lim WH, Kang J, **Park KW**, Oh S, Lip GYH. Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study. *PLoS One.* 2019 Jan 15;14(1):e0209593. doi: 10.1371/journal.pone.0209593. eCollection 2019. PMID: 30645601
88. Rhee TM, **Park KW (corresponding author)**, Kim CH, Kang J, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Dual Antiplatelet Therapy Duration Determines Outcome After 2- But Not 1-Stent Strategy in Left Main Bifurcation Percutaneous Coronary Intervention. *JACC Cardiovasc Interv.* 2018 Dec 24;11(24):2453-2463.

89. Jang JY, Shin DH, Kim JS, Hong SJ, Ahn CM, Kim BK, Ko YG, Choi D, Hong MK, **Park KW**, Gwon HC, Kim HS, Jang Y. Optimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome. *PLoS One*. 2018 Nov 26;13(11):e0207386.
90. Lee MS, Shlofmitz E, **Park KW**, Goldberg A, Jeremias A, Shlofmitz R. Orbital Atherectomy of Severely Calcified Unprotected Left Main Coronary Artery Disease: One-Year Outcomes. *J Invasive Cardiol*. 2018 Jul;30(7):270-274. PMID: 29958177
91. Kang J, **Park KW(corresponding author)**, Lee MS, Zheng C, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. The natural course of nonculprit coronary artery lesions; analysis by serial quantitative coronary angiography. *BMC Cardiovasc Disord*. 2018 Jun 28;18(1):130. doi: 10.1186/s12872-018-0870-9. PMID: 29954346
92. Lee MS, Shlofmitz E, Lluri G, **Park KW**, Hollowed J, Shlofmitz R. One-Year Outcomes of Orbital Atherectomy of Long, Diffusely Calcified Coronary Artery Lesions. *J Invasive Cardiol*. 2018 Jun;30(6):230-233. PMID: 29799426
93. Lee MS, Lluri G, Finch W, **Park KW**. Role of Percutaneous Coronary Intervention in the Treatment of Cardiac Allograft Vasculopathy. *Am J Cardiol*. 2018 May 1;121(9):1051-1055. doi: 10.1016/j.amjcard.2018.01.025. Epub 2018 Feb 6. PMID: 29598855
94. Rhee TM, Lee JM, Shin ES, Hwang D, Park J, Jeon KH, Kim HL, Yang HM, Han JK, **Park KW**, Hahn JY, Koo BK, Kim SH, Kim HS. Impact of Optimized Procedure-Related Factors in Drug-Eluting Balloon Angioplasty for Treatment of In-Stent Restenosis. *JACC Cardiovasc Interv*. 2018 May 28;11(10):969-978. doi: 10.1016/j.jcin.2018.02.002. PMID: 29798774
95. Kang J, Han JK, Ahn Y, Chae SC, Kim YJ, Chae IH, Hur SH, Seong IW, Chae JK, Cho MC, Seung KB, Jeong MH, Yang HM, **Park KW**, Kang HJ, Koo BK, Kim HS; investigators for Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH). Third-Generation P2Y12 Inhibitors

- in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study. *Thromb Haemost.* 2018 Mar;118(3):591-600. doi: 10.1055/s-0038-1626697. Epub 2018 Mar 13. PMID: 29534250
96. Hwang D, **Park KW (corresponding author)**, Lee JM, Rhee TM, Hong MK, Jang YS, Valgimigli M, Colombo A, Gilard M, Palmerini T, Stone GW, Kim HS. Efficacy and Safety of Dual Antiplatelet Therapy after Coronary Stenting in Patients with Chronic Kidney Disease. *Am Heart J.* 2018 Mar;197:103-112. doi: 10.1016/j.ahj.2017.11.013. Epub 2017 Dec 6.
97. Rhee TM, **Park KW (corresponding author)**, Lee JM, Lee MS, Jeon KH, Kang HJ, Koo BK, Rhew JY, Cha KS, Bae JH, Han KR, Park SH, Park WJ, Rha SW, Oh SK, Kwon HM, Seung KB, Ahn T, Kim SH, Kim HS. Predictors and Long-Term Clinical Outcome of Longitudinal Stent Deformation: Insights From Pooled Analysis of Korean Multicenter Drug-Eluting Stent Cohort. *Circ Cardiovasc Interv.* 2017 Nov;10(11):e005518. doi: 10.1161/CIRCINTERVENTIONS.117.005518. PMID: 29146671
98. Chung J, Han JK, Kim YJ, Kim CJ, Ahn Y, Chan Cho M, Chae SC, Chae IH, Chae JK, Seong IW, Yang HM, **Park KW**, Kang HJ, Koo BK, Jeong MH, Kim HS; investigators for Korea Acute Myocardial Infarction Registry (KAMIR). Benefit of Vasodilating β -Blockers in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention: Nationwide Multicenter Cohort Study. *J Am Heart Assoc.* 2017 Oct 24;6(10). pii: e007063. doi: 10.1161/JAHA.117.007063.
99. Yang HM, Seo KW, Yoon J, Kim HS, Chang K, Lim HS, Choi BJ, Choi SY, Yoon MH, Lee SH, Ahn SG, Youn YJ, Lee JW, Koo BK, **Park KW**, Yang HM, Han JK, Seung KB, Chung WS, Kim PJ, Koh YS, Park HJ, Tahk SJ. Clinical and Angiographic Outcomes of the First Korean-made Sirolimus-Eluting Coronary Stent with Abluminal Bioresorbable Polymer. *Korean Circ J.* 2017 Sep 18. doi: 10.4070/kcj.2017.0094. [Epub ahead of print]
100. Kim CH, Han JK, Yang HM, **Park KW**, Lee HY, Kang HJ, Koo BK,

Lee N, Cha TJ, Yang TH, Jeong MH, Yoon MH, Lee SU, Lee SJ, Kim JW, Cho JM, Han KR, Pyun WB, Kim HS. Study protocol for a randomised controlled trial: harmonising optimal strategy for treatment of coronary artery stenosis - coronary intervention with next-generation drug-eluting stent platforms and abbreviated dual antiplatelet therapy (HOST-IDEA) trial. *BMJ Open*. 2017 Oct 11;7(10):e016617. doi: 10.1136/bmjopen-2017-016617.

101. **Park KW**, Rhee TM, Kang HJ, Koo BK, Gwon HC, Yoon JH, Lim DS, Chae IH, Han KR, Ahn T, Jeong MH, Jeon DW, Jang YS, Kim HS. Randomized Prospective Comparison of Everolimus-Eluting vs. Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention- 3-Year Clinical Outcomes of the EXCELLENT Randomized Trial. *Circ J*. 2017 Sep 30. doi: 10.1253/circj.CJ-17-0677. [Epub ahead of print]
102. Kang J, **Park KW**, Kim HS. How far have we come with bioresorbable vascular scaffolds, and where should we go? *Cardiovasc Diagn Ther*. 2017 Jun;7(Suppl 2):S86-S90. doi: 10.21037/cdt.2017.01.11.
103. Kang J, Han JK, Yang HM, **Park KW**, Kang HJ, Koo BK, Kim HS. Bioresorbable Vascular Scaffolds - Are We Facing a Time of Crisis or One of Breakthrough? *Circ J*. 2017 Jul 25;81(8):1065-1074.
104. Lee MS, **Park KW**, Shlofmitz E, Shlofmitz RA. Comparison of Rotational Atherectomy Versus Orbital Atherectomy for the Treatment of Heavily Calcified Coronary Plaques. *Am J Cardiol*. 2017 May 1;119(9):1320-1323. doi: 10.1016/j.amjcard.2017.01.025. Epub 2017 Feb 10. PMID: 28258729
105. Palmerini T, Bacchi Reggiani L, Della Riva D, Romanello M, Feres F, Abizaid A, Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, **Park KW**, Colombo A, Chieffo A, Ahn JM, Park SJ, Schüpke S, Kastrati A, Montalescot G, Steg PG, Diallo A, Vicaut E, Helft G, Biondi-Zoccai G, Xu B, Han Y, Genereux P, Bhatt DL, Stone GW. Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary

Stenting. *J Am Coll Cardiol.* 2017 Apr 25;69(16):2011-2022.

106. Lee H, Koo BK, **Park KW**, Shin ES, Lim SW, Rha SW, Bae JW, Jeon DW, Oh SK, Hur SH, Kim BS, Lee JH, Park TH, Lee NH, Kim HS; HOST-EXAM investigators. A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial. *Am Heart J.* 2017 Mar;185:17-25.
107. Kim TK, Hong DM, Choi YH, Koo CH, Cho YJ, Park JB, **Park KW**, Kim HS, Jeon Y. Preoperative Serum Alkaline Phosphatase and Clinical Outcome of Off-Pump Coronary Artery Bypass Surgery. *Circ J.* 2017 May 25;81(6):799-805.
108. Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A, Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, **Park KW**, Colombo A, Chieffo A, Sangiorgi D, Biondi-Zoccai G, G n reux P, Angelini GD, Pufulete M, White J, Bhatt DL, Stone GW. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. *Eur Heart J.* 2017 Apr 7;38(14):1034-1043.
109. Lee JM, Rhee TM, Hahn JY, Hwang D, Park J, **Park KW**, Kim HL, Kim SH, Chae IH, Doh JH, Jeon KH, Choi YJ, Park JS, Choi SH, Gwon HC, Koo BK, Alfonso F, Kim HS. Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry. *Int J Cardiol.* 2017 Mar 1;230:181-190.
110. Kim JY, Yang HM, Lee JE, Kim BK, Jin S, Lee J, **Park KW**, Cho HJ, Kwon YW, Lee HY, Kang HJ, Oh BH, Park YB, Kim HS. Activation of

Protein Kinase G (PKG) Reduces Neointimal Hyperplasia, Inhibits Platelet Aggregation, and Facilitates Re-endothelialization. *Sci Rep*. 2016 Nov 11;6:36979

111. Gargiulo G, Windecker S, da Costa BR, Feres F, Hong MK, Gilard M, Kim HS, Colombo A, Bhatt DL, Kim BK, Morice MC, **Park KW**, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. *BMJ*. 2016 Nov 3;355:i5483.
112. Lee JM, Kang J, Lee E, Hwang D, Rhee TM, Park J, Kim HL, Lee SE, Han JK, Yang HM, **Park KW**, Na SH, Kang HJ, Koo BK, Kim HS. Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era: Pooled Analysis of the Korean Multicenter Drug-Eluting Stent Registry. *JACC Cardiovasc Interv*. 2016 Oct 24;9(20):2097-2109.
113. Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid A, Costa RA, Hong MK, Kim BK, Jang Y, Kim HS, **Park KW**, Gilard M, Morice MC, Sawaya F, Sardella G, Genereux P, Redfors B, Leon MB, Bhatt DL, Stone GW, Colombo A. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. *J Am Coll Cardiol*. 2016 Oct 25;68(17):1851-1864.
114. Song PS, Song YB, Lee JM, Hahn JY, Choi SH, Choi JH, Lee SH, **Park KW**, Kim HS, Jang Y, Seung KB, Oh JH, Gwon HC. Major Predictors of Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Coronary Bifurcation Lesions With 2-Stent Strategy: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts. *JACC Cardiovasc Interv*. 2016 Sep 26;9(18):1879-86. doi: 10.1016/j.jcin.2016.06.049.
115. Seo JB, Shin DH, **Park KW**, Koo BK, Gwon HC, Jeong MH, Seong IW, Rha SW, Yang JY, Park SJ, Yoon JH, Han KR, Park JS, Hur SH, Tahk SJ, Kim HS. Predictors for Side Branch Failure During Provisional Strategy of Coronary Intervention for Bifurcation Lesions (from the Korean Bifurcation

- Registry). *Am J Cardiol.* 2016 Sep 15;118(6):797-803. doi: 10.1016/j.amjcard.2016.06.049.
116. Im MS, Kim HL, Kim SH, Lim WH, Seo JB, Chung WY, Zo JH, Kim MA, **Park KW**, Koo BK, Kim HS, Chae IH, Cho DJ, Ahn Y, Jeong MH; Other Korea Acute Myocardial Infarction Registry (KAMIR) and Korea Working Group on Myocardial Infarction (KorMI) Investigators. Different prognostic factors according to left ventricular systolic function in patients with acute myocardial infarction. *Int J Cardiol.* 2016 Jun 23;221:90-96.
117. Kang J, **Park KW**, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Usefulness of the Baseline Syntax Score to Predict 3-Year Outcome After Complete Revascularization by Percutaneous Coronary Intervention. *Am J Cardiol.* 2016 Sep 1;118(5):641-6.
118. Lee SE, Yu CW, Park K, **Park KW**, Suh JW, Cho YS, Youn TJ, Chae IH, Choi DJ, Jang HJ, Park JS, Na SH, Kim HS, Kim KB, Koo BK. Physiological and clinical relevance of anomalous right coronary artery originating from left sinus of Valsalva in adults. *Heart.* 2016 Jan;102(2):114-9.
119. Park SD, Koo BK, Oh IY, Yoon CH, Park JJ, Yang HM, **Park KW**, Lee HY, Kang HJ, Kim HS. Effects of celecoxib on vascular changes after coronary intervention: A serial volumetric intravascular ultrasound analysis from the mini-COREA randomized clinical trial. *Int J Cardiol.* 2015 Sep 12;202:240-243.
120. Lee JM, Jung JH, **Park KW**, Shin ES, Oh SK, Bae JW, Rhew JY, Lee N, Kim DB, Kim U, Han JK, Lee SE, Yang HM, Kang HJ, Koo BK, Kim S, Cho YK, Shin WY, Lim YH, Rha SW, Kim SY, Lee SY, Kim YD, Chae IH, Cha KS, Kim HS. Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUction of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial. *Trials.* 2015 Sep 15;16:409. doi: 10.1186/s13063-015-0925-5.

121. Lee JM, Hahn JY, Kang J, **Park KW**, Chun WJ, Rha SW, Yu CW, Jeong JO, Jeong MH, Yoon JH, Jang Y, Tahk SJ, Gwon HC, Koo BK, Kim HS. Differential Prognostic Effect Between First- and Second-Generation Drug-Eluting Stents in Coronary Bifurcation Lesions: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts. *JACC Cardiovasc Interv.* 2015 Aug 24;8(10):1318-31.
122. Seo JB, **Park KW**, Lee HY, Kang HJ, Koo BK, Kim SH, Kim HS. Comparison of Angiographic Outcomes of Side Branch Ostium at Bifurcation Coronary Lesion between Two-stent and One-stent Techniques. *J Korean Med Sci.* 2015 Jul;30(7):889-94.
123. Kim HK, Jeong MH, Seo HW, Ahn JH, Cho KH, Hong YJ, Kim JH, Ahn Y, Cho JG, Park JC, **Park KW**, Kim HS, Lee SR, Chae JK; Korea Acute Myocardial Infarction Registry Investigators. Clinical impacts of high-sensitivity C-reactive protein reduction for secondary prevention in Asian patients with one-year survivor after acute myocardial infarction. *Int J Cardiol.* 2015 Aug 15;193:20-2.
124. Lee JM, **Park KW (corresponding author)**, Koo BK, Kim HS. Stenting of coronary bifurcation lesions: a literature and technical review. *Curr Cardiol Rep.* 2015 Jun;17(6):45. doi: 10.1007/s11886-015-0595-7.
125. Cho KH, Jeong MH, **Park KW**, Kim HS, Lee SR, Chae JK, Hong YJ, Kim JH, Ahn Y, Cho JG, Park JC; KAMIR (Korea Acute Myocardial Infarction Registry) Investigators. Comparison of the effects of two low-density lipoprotein cholesterol goals for secondary prevention after acute myocardial infarction in real-world practice: $\geq 50\%$ reduction from baseline versus <70 mg/dL. *Int J Cardiol.* 2015;187:478-85.
126. Palmerini T, Sangiorgi D, Valgimigli M, Biondi-Zoccai G, Feres F, Abizaid A, Costa RA, Hong MK, Kim BK, Jang Y, Kim HS, **Park KW**, Mariani A, Della Riva D, Genereux P, Leon MB, Bhatt DL, Bendetto U, Rapezzi C, Stone GW. Short- versus long-term dual antiplatelet therapy after

- drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. *J Am Coll Cardiol*. 2015 Mar 24;65(11):1092-102.
127. Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, Abizaid A, Hong MK, Kim BK, Jang Y, Kim HS, **Park KW**, Genereux P, Bhatt DL, Orlandi C, De Servi S, Petrou M, Rapezzi C, Stone GW. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. *Lancet*. 2015 Jun 13;385(9985):2371-82.
128. Lee JM, Park J, Kang J, Jeon KH, Jung JH, Lee SE, Han JK, Kim HL, Yang HM, **Park KW**, Kang HJ, Koo BK, Kim HS. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials. *JACC Cardiovasc Interv*. 2015 Mar;8(3):382-94.
129. Lee JM, Park J, Kang J, Jeon KH, Jung JH, Lee SE, Han JK, Kim HL, Yang HM, **Park KW**, Kang HJ, Koo BK, Kim SH, Kim HS. The efficacy and safety of mechanical hemodynamic support in patients undergoing high-risk percutaneous coronary intervention with or without cardiogenic shock: Bayesian approach network meta-analysis of 13 randomized controlled trials. *Int J Cardiol*. 2015 Apr 1;184:36-46.
130. Lim WH, Koo BK, Nam CW, Doh JH, Park JJ, Yang HM, **Park KW**, Kim HS, Takashima H, Waseda K, Amano T, Kato D, Kurita A, Oi M, Toyofuku M, van Nunen L, Pijls NH. Variability of fractional flow reserve according to the methods of hyperemia induction. *Catheter Cardiovasc Interv*. 2015 May;85(6):970-6.
131. Lee MS, Rha SW, **Park KW**, Kim MH. Is heparin an acceptable anticoagulant when glycoprotein IIb/IIIa inhibitors are not used? *JACC Cardiovasc Interv*. 2015 Jan;8(1 Pt B):223-224. doi: 10.1016/j.jcin.2014.07.019. Epub 2014 Nov 1. PMID: 25616929
132. Lee JM, Park J, Jeon KH, Jung JH, Lee SE, Han JK, Kim HL, Yang

- HM, **Park KW**, Kang HJ, Koo BK, Jo SH, Kim HS. Efficacy of short-term high-dose statin pretreatment in prevention of contrast-induced acute kidney injury: updated study-level meta-analysis of 13 randomized controlled trials. *PLoS One*. 2014 Nov 4;9(11):e111397. doi: 10.1371/journal.pone.0111397. eCollection 2014.
133. Kim HL, Kim SH, Seo JB, Chung WY, Zo JH, Kim MA, **Park KW**, Koo BK, Kim HS, Chae IH, Choi DJ, Cho MC, Kim YJ, Kim JH, Ahn Y, Jeong MH; Other Korea Acute Myocardial Infarction Registry, Korea Working Group on Myocardial Infarction Investigators. Influence of second- and third-degree heart block on 30-day outcome following acute myocardial infarction in the drug-eluting stent era. *Am J Cardiol*. 2014 Dec 1;114(11):1658-62.
134. Lee JM, **Park KW(co-first author)**, Han JK, Yang HM, Kang HJ, Koo BK, Bae JW, Woo SI, Park JS, Jin DK, Jeon DW, Oh SK, Park JS, Kim DI, Hyon MS, Jeon HK, Lim DS, Kim MG, Rha SW, Her SH, Hwang JY, Kim S, Choi YJ, Kang JH, Moon KW, Jang Y, Kim HS. Three-Year Patient-Related and Stent-Related Outcomes of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World Practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries). *Am J Cardiol*. 2014 Aug 12. pii:S0002-9149(14)01586-0. doi: 10.1016/j.amjcard.2014.07.065. [Epub ahead of print]
135. Lee MS, Yang T, Mahmud E, **Park KW**, Kim HS, Kim MH, Dangas G, Hermiller J, Krucoff M, Rutledge D. Clinical outcomes in the percutaneous coronary intervention of in-stent restenosis with everolimus-eluting stents. *J Invasive Cardiol*. 2014 Sep;26(9):420-6. PubMed PMID: 25198484.
136. **Park KW**, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, Rhew JY, Hwang SH, Lee SY, Kang TS, Kwak CH, Hong BK, Yu CW, Seong I, Ahn TH, Lee HC, Lim SW, Kim HS. Everolimus-Eluting Xience V/Promus versus Zotarolimus-Eluting Resolute Stents in Patients with Diabetes. *JACC Cardiovasc Interv*. 2014 May;7(5):471-81.

137. **Park KW**, Kang SH, Kang HJ, Koo BK, Park BE, Cha KS, Rhew JY, Jeon HK, Shin ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW, Kwon HM, Hur SH, Ryu J, Lee B, Park Y, Chae IH, Kim HS. A Randomized Comparison of Platinum Chromium-based Everolimus-Eluting Stent versus Cobalt Chromium-based Zotarolimus-Eluting Stent in All-Comers Receiving Percutaneous Coronary Intervention (HOST-ASSURE): A Randomized Controlled Non-Inferiority Trial. *J Am Coll Cardiol*. 2014 Jul 1;63(25 Pt A):2805-16. PMID: 24814486
138. Kim JH, **Park KW(co-first author)**, Lim WH, Shin DH, Chae IH, Choi DJ, Kim HS. Comparison of 2-year clinical outcomes between zotarolimus-, sirolimus-, and paclitaxel-eluting stents in real life clinical practice. *Catheter Cardiovasc Interv*. 2014 Feb 15;83(3):349-59.
139. **Park KW**, Kang J, Kang SH, Ahn HS, Kang HJ, Koo BK, Chae IH, Youn TJ, Oh BH, Park YB, Kandzari D, Kim HS. The impact of residual coronary lesions on clinical outcomes after percutaneous coronary intervention: Residual SYNTAX score after percutaneous coronary intervention in patients from the Efficacy of Xience/Promus versus Cypher in rEDucing Late Loss after stENTing (EXCELLENT) registry. *Am Heart J*. 2014 Mar;167(3):384-392.
140. Han JK, Koo BK, **Park KW**, Ben-Dor I, Waksman R, Pichard A, Nam CW, Doh JH, Murata N, Tanaka N, Lee CH, Gonzalo N, Escaned J, Costa MA, Kubo T, Akasaka T, Hu X, Wang J, Yang HM, Yoon MH, Tahk SJ, Ma S, Park SK, Kim HS. Optimal intravascular ultrasound criteria for defining the functional significance of intermediate coronary stenosis: an international multicenter study. *Cardiology*. 2014;127(4):256-62.
141. Kang SH, **Park KW(co-first author)**, Kang DY, Lim WH, Park KT, Han JK, Kang HJ, Koo BK, Oh BH, Park YB, Kandzari DE, Cohen DJ, Hwang SS, Kim HS. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. *Eur Heart J*. 2014 May;35(17):1147-58.

142. Kang SH, Park KH, Ahn HS, **Park KW**, Hong YJ, Koo BK, Jeong MH, Kim HS. Everolimus-eluting versus sirolimus-eluting coronary stents in patients with and without diabetes mellitus. *EuroIntervention*. 2014 May 20;10(1):74-82.
143. Kim KH, Doh JH, Koo BK, Min JK, Erglis A, Yang HM, **Park KW**, Lee HY, Kang HJ, Kim YJ, Lee SY, Kim HS. A novel noninvasive technology for treatment planning using virtual coronary stenting and computed tomography-derived computed fractional flow reserve. *JACC Cardiovasc Interv*. 2014 Jan;7(1):72-8.
144. Kim YG, Oh IY, Kwon YW, Han JK, Yang HM, **Park KW**, Lee HY, Kang HJ, Koo BK, Kim HS. Mechanism of edge restenosis after drug-eluting stent implantation. Angulation at the edge and mechanical properties of the stent. *Circ J*. 2013;77(12):2928-35.
145. **Park KW**, Kang SH, Park JJ, Yang HM, Kang HJ, Koo BK, Park BE, Cha KS, Rhew JY, Jeon HK, Shin ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW, Kwon HM, Chae IH, Kim HS. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen). *JACC Cardiovasc Interv*. 2013 Sep;6(9):932-42.
146. **Park KW**, Kang J, Kang SH, Ahn HS, Lee HY, Kang HJ, Koo BK, Chae IH, Youn TJ, Oh BH, Park YB, Kandzari DE, Kim HS. Usefulness of the SYNTAX and clinical SYNTAX scores in predicting clinical outcome after unrestricted use of sirolimus- and everolimus-eluting Stents. *Circ J*. 2013;77(12):2912-21.
147. Lee S, Lee HY, **Park KW**, Kang HJ, Koo BK, Kim HS, Choi DJ, Kim MA, Oh BH. Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial.

Am J Cardiovasc Drugs. 2013 Dec;13(6):413-24.

148. Seo JB, **Park KW**, Lee HY, Kang HJ, Koo BK, Kim SH, Kim HS. Comparison of Two Different Strategies of Intravascular Ultrasound Guidance during Percutaneous Coronary Intervention; Routine versus Selective. Korean Circ J. 2013 May;43(5):303-8. doi: 10.4070/kcj.2013.43.5.303. Epub 2013 May 31. PMID: 23755076
149. **Park KW**, Lim WH, Ahn HS, Kang SH, Han JK, Lee SE, Cho JH, Gwon HC, Lee SY, Rhew JY, Kim W, Chae IH, Kim HS. Everolimus- versus sirolimus-eluting stents for the treatment of unprotected left main coronary artery stenosis (results from the EXCELLENT registry). Int J Cardiol. 2013 Oct 3;168(3):2738-44.
150. Seo JB, Kang SH, Hur SH, **Park KW**, Youn TJ, Park JS, Yang HM, Lee HY, Kang HJ, Koo BK, Bae JH, Kim SW, Moon KW, Choi JW, Lee SG, Chung WY, Kim SJ, Kim DI, Kim BO, Hyon MS, Park KS, Cha TJ, Yoo CW, Jeon HK, Kim HS. Randomized trial comparing the efficacy between different types of paclitaxel-eluting stents: the comparison of efficacy between COroflex PLEASE ANd Taxus stent (ECO-PLEASANT) randomized controlled trial. Am Heart J. 2013 May;165(5):733-43.
151. Valgimigli M, Park SJ, Kim HS, **Park KW**, Park DW, Tricoci P, Ferrante G. Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials. Int J Cardiol. 2013 Oct 3;168(3):2579-87.
152. **Park KW**, Kang J, Park JJ, Yang HM, Kwon YW, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. Thiazolidinedione usage is associated with decreased response to clopidogrel in DM patients. Int J Cardiol. 2013 Sep 20;168(1):608-10. doi: 10.1016/j.ijcard.2013.01.225. Epub 2013 Mar 24. PMID: 23531377
153. **Park KW**, Park JJ, Kang J, Jeon KH, Kang SH, Han JK, Lee SE, Yang HM, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI. PLoS One. 2013;8(2):e52779

154. Park JJ, **Park KW(co-first author)**, Kang J, Jeon KH, Kang SH, Ahn HS, Han JK, Koh JS, Lee SE, Yang HM, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. CYP3A4 genetic status may be associated with increased vulnerability to the inhibitory effect of calcium-channel blockers on clopidogrel. *Circ J*. 2013;77(5):1289-96. doi: 10.1253/circj.cj-12-0682. Epub 2013 Feb 9. PMID: 23400261
155. Jang HJ, Koo BK, Lee HS, Park JB, Kim JH, Seo MK, Yang HM, **Park KW**, Nam CW, Doh JH, Kim HS. Safety and efficacy of a novel hyperaemic agent, intracoronary nicorandil, for invasive physiological assessments in the cardiac catheterization laboratory. *Eur Heart J*. 2013 Jul;34(27):2055-62. doi: 10.1093/eurheartj/ehs040. Epub 2013 Feb 8. PMID: 23396491
156. **Park KW**, Kang SH, Velders MA, Shin DH, Hahn S, Lim WH, Yang HM, Lee HY, Van Boven AJ, Hofma SH, Kang HJ, Koo BK, Oh BH, Park YB, Kandzari DE, Kim HS. Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials. *Am Heart J*. 2013 Feb;165(2):241-50.
157. **Park KW**, Lee JM, Kang SH, Ahn HS, Yang HM, Lee HY, Kang HJ, Koo BK, Cho J, Gwon HC, Lee SY, Chae IH, Youn TJ, Chae JK, Han KR, Yu CW, Kim HS. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries. *J Am Coll Cardiol*. 2013 Feb 5;61(5):536-44.
158. Park JJ, **Park KW(co-first author)**, Kang J, Jeon KH, Kang SH, Ahn HS, Han JK, Koh JS, Lee SE, Yang HM, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents. *Int J Cardiol*. 2013 Feb 10;163(1):79-86.
159. Park JB, Kang DY, Yang HM, Cho HJ, **Park KW**, Lee HY, Kang HJ, Koo BK, Kim HS. Serum alkaline phosphatase is a predictor of mortality, myocardial infarction, or stent thrombosis after implantation of coronary drug-

- eluting stent. *Eur Heart J*. 2013 Mar;34(12):920-31.
160. Koo BK, Lee SP, Lee JH, **Park KW**, Suh JW, Cho YS, Chung WY, Doh JH, Nam CW, Yu CW, Lee BK, Vassilev D, Gil R, Lim HS, Tahk SJ, Kim HS. Assessment of clinical, electrocardiographic, and physiological relevance of diagonal branch in left anterior descending coronary artery bifurcation lesions. *JACC Cardiovasc Interv*. 2012 Nov;5(11):1126-32.
161. Yoon YE, Choi JH, Kim JH, **Park KW**, Doh JH, Kim YJ, Koo BK, Min JK, Erglis A, Gwon HC, Choe YH, Choi DJ, Kim HS, Oh BH, Park YB. Noninvasive Diagnosis of Ischemia-Causing Coronary Stenosis Using CT Angiography: Diagnostic Value of Transluminal Attenuation Gradient and Fractional Flow Reserve Computed From Coronary CT Angiography Compared to Invasively Measured Fractional Flow Reserve. *JACC Cardiovasc Imaging*. 2012 Nov;5(11):1088-96. doi: 10.1016/j.jcmg.2012.09.002.PubMed PMID: 23153908.
162. Kim HL, Koo BK, Nam CW, Doh JH, Kim JH, Yang HM, **Park KW**, Lee HY, Kang HJ, Cho YS, Youn TJ, Kim SH, Chae IH, Choi DJ, Kim HS, Oh BH, Park YB. Clinical and physiological outcomes of fractional flow reserve-guided percutaneous coronary intervention in patients with serial stenoses within one coronary artery. *JACC Cardiovasc Interv*. 2012 Oct;5(10):1013-8.
163. Kang DY, Yang HM, **Park KW**, Lee SR, Lee MH, Lee DW, Lee HY, Kang HJ, Koo BK, Chae IH, Choi DJ, Kim HS, Kim CH. Lack of association between low density lipoprotein particle size and on-treatment platelet reactivity in patients with coronary artery disease. *Korean Circ J*. 2012 Aug;42(8):551-7. Epub 2012 Aug 31.
164. Park JJ, Chae IH, Cho YS, Kim SW, Yang HM, Seo JB, Kim SY, Oh IY, Yoon CH, Suh JW, **Park KW**, Chung WY, Youn TJ, Choi DJ, Kim HS. The recanalization of chronic total occlusion leads to lumen area increase in distal reference segments in selected patients: an intravascular ultrasound study. *JACC Cardiovasc Interv*. 2012 Aug;5(8):827-36.
165. Kang HJ, Kim MK, Lee HY, **Park KW**, Lee W, Cho YS, Koo BK, Choi DJ, Park YB, Kim HS. Five-year results of intracoronary infusion of the

- mobilized peripheral blood stem cells by granulocyte colony-stimulating factor in patients with myocardial infarction. *Eur Heart J*. 2012 Aug 17.
166. Song PS, Hahn JY, Song YB, Choi JH, Choi SH, Kang GH, Ahn KT, Lim WH, **Park KW**, Kim HS, Gwon HC. Effects of 600 mg versus 300 mg loading dose of clopidogrel in Asian patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: long-term follow-up study. *Yonsei Med J*. 2012 Sep;53(5):906-14.
167. Lee MS, **Park KW(co-first author)**, Kang SH, Sheiban I, Mahmud E, Thani KB, Cheng R, Cho JH, Jin DK, Gwon HC, Chae IH, Aragon J, Gillis K, Stone GW, Kim HS. Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with everolimus-eluting stents. *J Invasive Cardiol*. 2012 Jul;24(7):316-9.
168. **Park KW**, Kang J, Park JJ, Yang HM, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. *Heart*. 2012 Sep;98(18):1366-72.
169. Seo MK, Koo BK, Kim JH, Shin DH, Yang HM, **Park KW**, Lee HY, Kang HJ, Kim HS, Oh BH, Park YB. Comparison of hyperemic efficacy between central and peripheral venous adenosine infusion for fractional flow reserve measurement. *Circ Cardiovasc Interv*. 2012 Jun;5(3):401-5.
170. **Park KW**, Kang SH, Kang J, Jeon KH, Park JJ, Han JK, Koh JS, Lee SE, Yang HM, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of 'smokers' paradox'. *Heart*. 2012 Jul;98(13):1000-6.
171. Koh JS, Koo BK, Kim JH, Yang HM, **Park KW**, Kang HJ, Kim HS, Oh BH, Park YB. Relationship between fractional flow reserve and angiographic and intravascular ultrasound parameters in ostial lesions: major epicardial vessel versus side branch ostial lesions. *JACC Cardiovasc Interv*. 2012 Apr;5(4):409-15.
172. Chung JW, Park KH, Lee MH, **Park KW**, Park JS, Kang HJ, Koo BK,

- Kwon YW, Kim HS. Benefit of complete revascularization in patients with multivessel coronary disease in the drug-eluting stent era. *Circ J*. 2012;76(7):1624-30.
173. **Park KW**, Kang SH, Yang HM, Lee HY, Kang HJ, Cho YS, Youn TJ, Koo BK, Chae IH, Kim HS. Impact of intravascular ultrasound guidance in routine percutaneous coronary intervention for conventional lesions: data from the EXCELLENT trial. *Int J Cardiol*. 2012 Apr 3. [Epub ahead of print] PubMed PMID: 22481046.
174. **Park KW**, Park BE, Kang SH, Park JJ, Lee SP, Cha KS, Rhew JY, Jeon HK, Shin ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW, Kwon HM, Chae IH, Kim HS; HOST investigators. *Trials*. 2012 Mar 31;13:29.
175. Kang HJ, Yoon EJ, Lee EJ, Kim MK, Suh JW, **Park KW**, Lee HY, Park KU, Cho YS, Koo BK, Chae IH, Choi DJ, Han KS, Kim HS, Park YB. Cotreatment with darbepoetin and granulocyte colony-stimulating factor is efficient to recruit proangiogenic cell populations in patients with acute myocardial infarction. *Cell Transplant*. 2012;21(5):1055-61.
176. Kang HJ, Oh IY, Chung JW, Yang HM, Suh JW, **Park KW**, Kwon TK, Lee HY, Cho YS, Youn TJ, Koo BK, Kang WY, Kim W, Rha SW, Bae JH, Chae IH, Choi DJ, Kim HS. Effects of Celecoxib On Restenosis after Coronary Intervention and Evolution of Atherosclerosis (Mini-COREA) Trial: celecoxib, a double-edged sword for patients with angina. *Eur Heart J*. 2012 Nov;33(21):2653-61.
177. Park K, **Park KW**, Rha SW, Bae JH, Hur SH, Park JS, Yoon JH, Jang Y, Jeong MH, Kim HS. Comparison of 5-year clinical outcomes between sirolimus-versus paclitaxel-eluting stent: Korean multicenter network analysis of 9000-patient cohort. *Circ Cardiovasc Interv*. 2012 Apr;5(2):174-84.
178. Park HE, Koo BK, **Park KW**, Paeng JC, Lee HY, Kang HJ, Kim HS. Diagnostic value of myocardial SPECT to detect in-stent restenosis after drug-eluting stent implantation. *Int J Cardiovasc Imaging*. 2012 Dec;28(8):2125-34.
179. Park K, Kim TE, **Park KW**, Kang HJ, Koo BK, Kim HS. Analysis of

- potential cost-savings after introduction of drug-eluting balloon angioplasty for in-stent restenosis or small vessel disease. *Korean Circ J.* 2011 Dec;41(12):705-11.
180. **Park KW**, Kim HS. Options to overcome clopidogrel response variability. *Circ J.* 2012;76(2):287-92. Epub 2012 Jan 12. Review.
181. Gwon HC, Hahn JY, **Park KW**, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. *Circulation.* 2012 Jan24;125(3):505-13.
182. Park JB, Kim BK, Kwon YW, Muller DN, Lee HC, Youn SW, Choi YE, Lee SW, Yang HM, Cho HJ, **Park KW**, Kim HS. Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion. *PLoS One* 2011;6(11): e28327.
183. **Park KW**, Kang SH, Kim HS. Response to "Sirolimus or paclitaxel drug eluting stent in left main disease: the winner is...". *Int J Cardiol.* 2012 Jan 26;154(2):192-3. doi: 10.1016/j.ijcard.2011.10.079. Epub 2011 Nov 9. PMID: 22078987
184. **Park KW**, Lim WH, Kim JH, Kang SH, Seo JW, Song YB, Hahn JY, Lee HY, Kang HJ, Cho YS, Youn TJ, Koo BK, Choi SH, Chae IH, Gwon HC, Choi DJ, Kim HS. Comparison between zotarolimus-eluting stents and first generation drug-eluting stents in the treatment of patients with acute ST-segment elevation myocardial infarction. *Int J Cardiol.* 2013 Jun 5;166(1):118-25. doi: 10.1016/j.ijcard.2011.10.012. Epub 2011 Nov 5. PMID: 22062892
185. Shin DH, Koo BK, Waseda K, **Park KW**, Kim HS, Corral M, Lansky A, Honda Y, Fearon WF, Fitzgerald PJ. Discrepancy in the assessment of jailed side branch lesions by visual estimation and quantitative coronary angiographic analysis: comparison with fractional flow reserve. *Catheter Cardiovasc Interv.* 2011 Nov 1;78(5):720-6. doi: 10.1002/ccd.23049.

186. **Park KW**, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Jo SH, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Gwon HC, Jang YS, Kim HS. Everolimus-Eluting versus Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: The EXCELLENT Randomized Trial. *J Am Coll Cardiol*. 2011 Oct 25;58(18):1844-54.
187. **Park KW**, Jeon KH, Kang SH, Oh IY, Cho HJ, Lee HY, Kang HJ, Park SK, Koo BK, Oh BH, Park YB, Kim HS. Clinical Outcomes of High On-Treatment Platelet Reactivity in Koreans Receiving Elective Percutaneous Coronary Intervention (from Results of the CROSS VERIFY Study). *Am J Cardiol*. 2011 Dec 1;108(11):1556-63. Epub 2011 Aug 30.
188. Shin DH, **Park KW** (co-first author), Koo BK, Oh IY, Seo JB, Gwon HC, Jeong MH, Seong IW, Rha SW, Yang JY, Park SJ, Yoon JH, Han KR, Park JS, Hur SH, Tahk SJ, Kim HS. Comparing Two-Stent Strategies for Bifurcation Coronary Lesions: Which Vessel Should be Stented First, the Main Vessel or the Side Branch? *J Korean Med Sci*. 2011 Aug;26(8):1031-40. Epub 2011 Jul 27.
189. Lee SP, Bae JW, **Park KW**, Rha SW, Bae JH, Suh JW, Chae IH, Cho MC, Kim HS. Inhibitory Interaction Between Calcium Channel Blocker and Clopidogrel. *Circ J*. 2011 Aug 20. [Epub ahead of print]
190. Lee SP, **Park KW**(co-first author), Shin DH, Lee HY, Kang HJ, Koo BK, Suh JW, Youn TJ, Choi DJ, Chae IH, Kim HS. Efficacy of Predicting Thrombotic Events with Combination of Dual Point-of-Care Testing (POCT) after Drug-Eluting Stent Implantation for Coronary Heart Disease: Results from the CILON-T Randomized Trial POCT Substudy. *J Atheroscler Thromb*. 2011 Jul 26. [Epub ahead of print]
191. Koo BK, Yang HM, Doh JH, Choe H, Lee SY, Yoon CH, Cho YK, Nam CW, Hur SH, Lim HS, Yoon MH, **Park KW**, Na SH, Youn TJ, Chung WY, Ma S, Park SK, Kim HS, Tahk SJ. Optimal intravascular ultrasound criteria and their accuracy for defining the functional significance of intermediate coronary stenoses of different locations. *JACC Cardiovasc Interv*. 2011 Jul;4(7):803-11.

192. Oh IY, **Park KW (co-first author)**, Kang SH, Park JJ, Na SH, Kang HJ, Koo BK, Jeong YH, Hwang JY, Kwak CH, Park Y, Hwang SJ, Ko YG, Shin DJ, Jang Y, Kim HS. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. *Heart*. 2012 Jan;98(2):139-44.
193. Park K, Youn TJ, **Park KW**, Na SH, Lee HY, Kang HJ, Chung WY, Koo BK, Chae IH, Choi DJ, Kim HS, Oh BH, Park YB. Physiologic Evaluation of Myocardial Bridging: A New Analysis for an Old Disease. *Can J Cardiol*. 2011 Jun 2. [Epub ahead of print]
194. Kim JH, **Park KW**, (co-first) Lim WH, Shin DH, Na SH, Koo BK, Youn TJ, Chae IH, Choi DJ, Kim HS. Comparison of two-year clinical outcomes between zotarolimus-, sirolimus-, and paclitaxel-eluting stents in real life clinical practice. *Catheter Cardiovasc Interv*. 2011 Nov 22. doi: 10.1002/ccd.23428. [Epub ahead of print]
195. **Park KW**, Hwang SJ, Kwon DA, Oh BH, Park YB, Chae IH, Gwon HC, Park SJ, Seung KB, Ahn T, Yoon JH, Jang YS, Jeong MH, Tahk SJ, Kim HS; The Korea Stent Thrombosis Investigators. Characteristics and predictors of drug-eluting stent thrombosis: results from the multicenter 'Korea Stent Thrombosis (KoST)' registry. *Circ J*. 2011 Jun 24;75(7):1626-1632. Epub 2011 May 28.
196. Hwang SJ, **Park KW(co-first author)**, Kwon DA, Kang HJ, Koo BK, Chae IH, Gwon HC, Park SJ, Seung KB, Ahn T, Yoon JH, Jang YS, Jeong MH, Tahk SJ, Kim HS; The Korea Stent Thrombosis Investigators. High Plasma Interleukin-6 Is Associated With Drug-Eluting Stent Thrombosis. *Circ J*. 2011 May 25;75(6):1350-1357. Epub 2011 Apr 18.
197. Jang Y, Waterworth D, Lee JE, Song K, Kim S, Kim HS, **Park KW**, Cho HJ, Oh IY, Park JE, Lee BS, Ku HJ, Shin DJ, Lee JH, Jee SH, Han BG, Jang HY, Cho EY, Vallance P, Whittaker J, Cardon L, Mooser V. Carriage of the V279F null allele within the gene encoding Lp-PLA₂ is protective from coronary artery disease in South Korean males. *PLoS One*. 2011 Apr 5;6(4):e18208.

198. Na SH, Koo BK, Kim JC, Yang HM, **Park KW**, Kang HJ, Kim HS, Oh BH, Park YB. Evaluation of local flow conditions in jailed side branch lesions using computational fluid dynamics. *Korean Circ J*. 2011 Feb;41(2):91-6. doi: 10.4070/kcj.2011.41.2.91. Epub 2011 Feb 28. PMID: 21430994
199. **Park KW**, Park JJ, Lee SP, Oh IY, Suh JW, Yang HM, Lee HY, Kang HJ, Cho YS, Koo BK, Youn TJ, Chae IH, Choi DJ, Oh BH, Park YB, Kim HS. Cilostazol Attenuates On-Treatment Platelet Reactivity in Patients with CYP2C19 Loss of Function Alleles Receiving Dual Antiplatelet Therapy: a Genetic Substudy of the CILON-T Randomized Controlled Trial. *Heart*. 2011 Apr;97(8):641-7. Epub 2011 Feb 22.
200. Suh JW, Lee SP, **Park KW**, Lee HY, Kang HJ, Koo BK, Cho YS, Youn TJ, Chae IH, Choi DJ, Rha SW, Bae JH, Kwon TG, Bae JW, Cho MC, Kim HS. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stent implantation) trial. *J Am Coll Cardiol*. 2011 Jan 18;57(3):280-9. 26.
201. **Park KW**, Park JJ, Chae IH, Seo JB, Yang HM, Lee HY, Kang HJ, Cho YS, Yeon TJ, Chung WY, Koo BK, Choi DJ, Oh BH, Park YB, Kim HS. Clinical characteristics of coronary drug-eluting stent fracture: insights from a two-center des registry. *J Korean Med Sci*. 2011 Jan;26(1):53-8. Epub 2010 Dec 22.
202. **Park KW**, Park JJ, Jeon KH, Kang SH, Oh IY, Yang HM, Cho HJ, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. Enhanced Clopidogrel Responsiveness in Smokers. Smokers' Paradox Is Dependent on Cytochrome P450 CYP1A2 Status. *Arterioscler Thromb Vasc Biol*. 2011 Mar;31(3):665-71. Epub 2010 Dec 9.
203. **Park KW**, Park JJ, Jeon KH, Kang SH, Oh IY, Yang HM, Cho HJ, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. Clinical Predictors of High Posttreatment Platelet Reactivity to Clopidogrel in Koreans. *Cardiovasc Ther*. 2010 Dec 6. doi: 10.1111/j.1755-5922.2010.00249.x. [Epub ahead of print]

204. Lee SP, Shin DH, **Park KW**, Kang HJ, Koo BK, Cho YS, Yeon TJ, Chae IH, Choi DJ, Kim HS. Angiographic patterns of restenosis after percutaneous intervention of chronic total occlusive lesions with drug-eluting stents. *Int J Cardiol.* 2010 Nov 23. [Epub ahead of print]
205. Kim KH, Koo BK, Min HS, Park SK, Kim CH, **Park KW**, Park BJ, Jeong MH, Cho MC, Lee SR, Chae SC, Seong IW, Choi DJ, Kim HS. Comparison of drug-eluting versus bare-metal stent implantation in ST-elevation myocardial infarction patients with renal insufficiency: Results from the national registry in Korea. *Int J Cardiol.* 2010 Sep 29. [Epub ahead of print]
206. Lee SP, Suh JW, **Park KW**, Lee HY, Kang HJ, Koo BK, Chae IH, Choi DJ, Rha SW, Bae JW, Cho MC, Kwon TG, Bae JH, Kim HS; CILON-T investigators. Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. *Trials.* 2010 Aug 24;11:87.
207. Park SJ, Kim KH, Oh IY, Shin DH, Park KI, Seo MK, Chung JW, **Park KW**, Lee HY, Kang HJ, Koo BK, Youn TJ, Kim HS. Comparison of plain balloon and cutting balloon angioplasty for the treatment of restenosis with drug-eluting stents vs bare metal stents. *Circ J.* 2010 Sep;74(9):1837-45. Epub 2010 Jul 29.
208. **Park KW**, Kang SH, Park KH, Choi DH, Lee HY, Kang HJ, Cho YS, Yeon TJ, Chung WY, Koo BK, Chae IH, Choi DJ, Oh BH, Park YB, Kim HS. Sirolimus- vs. paclitaxel-eluting stents for the treatment of unprotected left main coronary artery stenosis: Complete 2-year follow-up of a two-center registry. *Int J Cardiol.* 2010 Jun 2. [Epub ahead of print]
209. Lee S, **Park KW**, Kim HS. Stentablation of an underexpanded stent in a heavily calcified lesion using rotational atherectomy. *J Cardiovasc Med (Hagerstown).* 2010 May 19. [Epub ahead of print]
210. Cho Y, Yang HM, **Park KW**, Chung WY, Choi DJ, Seo WW, Jeong KT, Chae SC, Lee MY, Hur SH, Chae JK, Seong IW, Yoon JH, Oh SK, Kim DI,

- Park KS, Rha SW, Jang YS, Bae JH, Hong TJ, Cho MC, Kim YJ, Jeong MH, Kim MJ, Park SK, Chae IH, Kim HS; KAMIR Investigators. Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation. *JACC Cardiovasc Interv.* 2010 May;3(5):498-506.
211. Chung JW, Yang HM, **Park KW**, Lee HY, Park JS, Kang HJ, Cho YS, Youn TJ, Koo BK, Chae IH, Choi DJ, Oh BH, Park YB, Kim HS. Long-term outcome of adjunctive celecoxib treatment after paclitaxel-eluting stent implantation for the complex coronary lesions: two-year clinical follow-up of COREA-TAXUS trial. *Circ Cardiovasc Interv.* 2010 Jun 1;3(3):243-8. Epub 2010 May 18.
212. **Park KW**, Kang SH, Chung WY, Lee HY, Park JS, Kang HJ, Cho YS, Youn TJ, Koo BK, Chae IH, Choi DJ, Hahn S, Park BJ, Kim HS. 'Real world' comparison of drug-eluting stents vs bare metal stents in the treatment of unselected patients with acute ST-segment elevation myocardial infarction. *Circ J.* 2010 May 25;74(6):1111-20. Epub 2010 Apr 20.
213. **Park KW**, Kim CH, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. Does 'Late Catch-Up' Exist In Drug-Eluting Stents? : Insights from a Serial Quantitative Coronary Angiography Analysis of Sirolimus versus Paclitaxel-Eluting Stents. *Am Heart J.* 2010 Mar;159(3):446-453.e3.
214. Lee SP, Kim SY, **Park KW**, Shin DH, Kang HJ, Koo BK, Suh JW, Cho YS, Yeon TJ, Chae IH, Choi DJ, Kim HS. Long-term clinical outcome of chronic total occlusive lesions treated with drug-eluting stents: comparison of sirolimus-eluting and paclitaxel-eluting stents. *Circ J.* 2010 Mar 25;74(4):693-700. Epub 2010 Mar 3.
215. Choi DH, **Park KW(co-first author)**, Yang HM, Lee HY, Park JS, Kang HJ, Kim YJ, Koo BK, Oh BH, Park YB, Kim HS. Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents. *Int J Cardiol* 2010 Feb 4. [Epub ahead of print].
216. Kang SH, Park KH, Choi DJ, **Park KW**, Chung WY, Lim C, Kim KB,

- Kim HS. Coronary artery bypass grafting versus drug-eluting stent implantation for left main coronary artery disease (from a two-center registry). *Am J Cardiol*. 2010 Feb 1;105(3):343-51.
217. Kim MS, Lee CS, Hur J, Cho HJ, Jun SI, Kim TY, Lee SW, Suh JW, **Park KW**, Lee HY, Kang HJ, Lee DS, Koh GY, Nakagami H, Morishita R, Park YB, Kim HS. Priming with angiopoietin-1 augments the vasculogenic potential of the peripheral blood stem cells mobilized with granulocyte colony-stimulating factor through a novel Tie2/Ets-1 pathway. *Circulation*. 2009 Dec 1;120(22):2240-50. Epub 2009 Nov 16.
218. Seo JB, Jeon HK, **Park KW**, Park JS, Bae JH, Kim SW, Moon KW, Choi JW, Lee SG, Chung WY, Youn TJ, Kim SJ, Kim DI, Kim BO, Hyon MS, Park KS, Cha TJ, Hwang HK, Hur SH, Kim HS. Efficacies of the new paclitaxel-eluting Coroflex Please stent in percutaneous coronary intervention; comparison of efficacy between Coroflex Please and Taxus (ECO-PLEASANT) trial: study rationale and design. *Trials*. 2009 Oct 23;10:98.
219. Choi DH, Suh JW, **Park KW**, Kang HJ, Kim HS. Assessment of the bioequivalence of brand and biogeneric formulations of abciximab for the treatment of acute coronary syndrome: a prospective, open-label, randomized, controlled study in Korean patients. *Clin Ther*. 2009 Aug;31(8):1804-11.
220. Kim YJ, Shin JI, **Park KW**, Lee HY, Kang HJ, Koo BK, Park BJ, Sohn DW, Oh BH, Park YB, Kim HS. The Effect of Granulocyte-Colony Stimulating Factor on Endothelial Function in Patients with Myocardial Infarction. *Heart* 2009 Aug;95(16):1320-5. doi: 10.1136/hrt.2008.143966. Epub 2009 May 20.
221. Kim JY, Cho HJ, Sir JJ, Kim BK, Hur J, Youn SW, Yang HM, Jun SI, **Park KW**, Hwang SJ, Kwon YW, Lee HY, Kang HJ, Oh BH, Park YB, Kim HS. Sulfasalazine induces haem oxygenase-1 via ROS-dependent Nrf2 signalling, leading to control of neointimal hyperplasia. *Cardiovasc Res*. 2009 Jun 1;82(3):550-60. Epub 2009 Feb 21.
222. **Park KW**, Cho YS, Chung JW, Yeon TJ, Chae IH, Choi DJ, Oh BH, Park YB, Chung WY. One year clinical and six month angiographic results of

- drug eluting stents for ST elevation acute myocardial infarction: 'Real World' comparison between Sirolimus- and Paclitaxel-eluting stents. *Int J Cardiol.* 2009 Jan 24;131(3):350-5.
223. **Park KW**, Yoon JH, Kim JS, Hahn JY, Cho YS, Chae IH, Gwon HC, Ahn T, Oh BH, Park JE, Shim WH, Shin EK, Jang YS, Kim HS. Efficacy of Xience/promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) trial: Study design and rationale of a Korean multicenter prospective randomized trial. *Am Heart J* 2009 May;157(5):811-817.e1
224. Kim YS, Koo BK, Seo JB, **Park KW**, Suh JW, Lee HY, Park JS, Kang HJ, Cho YS, Chung WY, Chae IH, Choi DJ, Kim HS, Oh BH, Park YB. The incidence and predictors of postprocedural incomplete stent apposition after angiographically successful drug-eluting stent implantation. *Catheter Cardiovasc Interv.* 2009 Jul 1;74(1):58-63. doi: 10.1002/ccd.21961. PMID: 19360868
225. Kim JY, Cho HJ, Sir JJ, Kim BK, Hur J, Youn SW, Yang HM, Jun SI, **Park KW**, Hwang SJ, Kwon YW, Lee HY, Kang HJ, Oh BH, Park YB, Kim HS. Sulfasalazine induces haem oxygenase-1 via ROS-dependent Nrf2 signalling, leading to control of neointimal hyperplasia. *Cardiovasc Res.* 2009 Jun 1;82(3):550-60. doi: 10.1093/cvr/cvp072. Epub 2009 Feb 21. PMID: 19234301
226. Lee CS, Kwon YW, Yang HM, Kim SH, Kim TY, Jin-Hur, **Park KW**, Cho HJ, Kang HJ, Park YB, Kim HS. New Mechanism of Rosiglitazone to Reduce Neointimal Hyperplasia. Activation of Glycogen Synthase Kinase-3{beta} Followed by Inhibition of MMP-9. *Arterioscler Thromb Vasc Biol.* 2009 Apr;29(4):472-9. Epub 2009 Feb 5.
227. Han JK, Lee HS, Yang HM, Hur J, Jun SI, Kim JY, Cho CH, Koh GY, Peters JM, **Park KW**, Cho HJ, Lee HY, Kang HJ, Oh BH, Park YB, Kim HS. Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway. *Circulation.* 2008 Sep 2;118(10):1021-33
228. **Park KW**, Kwon YW, Cho HJ, Shin JI, Kim YJ, Lee SE, Youn SW,

- Lee HC, Kang HJ, Shaul PW, Oh BH, Park YB, Kim HS. G-CSF exerts dual effects on endothelial cells--opposing actions of direct eNOS induction versus indirect CRP elevation. *J Mol Cell Cardiol.* 2008 Nov;45(5):670-8.
229. Chang SA, Lee EJ, Kang HJ, Zhang SY, Kim JH, Li L, Youn SW, Lee CS, Kim KH, Won JY, Sohn JW, **Park KW**, Cho HJ, Yang SE, Oh WI, Yang YS, Ho WK, Park YB, Kim HS. Impact of myocardial infarct proteins and oscillating pressure on the differentiation of mesenchymal stem cells: effect of acute myocardial infarction on stem cell differentiation. *Stem Cells.* 2008 Jul;26(7):1901-12.
230. Koo BK, **Park KW**, Kang HJ, Cho YS, Chung WY, Youn TJ, Chae IH, Choi DJ, Tahk SJ, Oh BH, Park YB, Kim HS. Physiological evaluation of the provisional side-branch intervention strategy for bifurcation lesions using fractional flow reserve. *Eur Heart J.* 2008 Mar;29(6):726-32.
231. Kang HJ, Kim YS, Koo BK, **Park KW**, Lee HY, Sohn DW, Oh BH, Park YB, Kim HS. Effects of stem cell therapy with G-CSF on coronary artery after drug-eluting stent implantation in patients with acute myocardial infarction. *Heart.* 2008 May;94(5):604-9.
232. Lee HY, You HJ, Won JY, Youn SW, Cho HJ, **Park KW**, Park WY, Seo JS, Park YB, Walsh K, Oh BH, Kim HS. Forkhead factor, FOXO3a, induces apoptosis of endothelial cells through activation of matrix metalloproteinases. *Arterioscler Thromb Vasc Biol.* 2008 Feb;28(2):302-8.
233. **Park KW**, Hwang KK, Cho HJ, Hur J, Yang HM, Yoon CH, Kang HJ, Oh BH, Park YB, Kim HS. Simvastatin enhances endothelial differentiation of peripheral blood mononuclear cells in hypercholesterolemic patients and induces pro-angiogenic cytokine IL-8 secretion from monocytes. *Clin Chim Acta.* 2008 Feb;388(1-2):156-66.
234. Lee HY, Youn SW, Kim JY, **Park KW**, Hwang CI, Park WY, Oh BH, Park YB, Walsh K, Seo JS, Kim HS. FOXO3a turns the tumor necrosis factor receptor signaling towards apoptosis through reciprocal regulation of c-Jun N-terminal kinase and NF-kappaB. *Arterioscler Thromb Vasc Biol.* 2008 Jan;28(1):112-20.

235. Hur J, Yang HM, Yoon CH, Lee CS, **Park KW**, Kim JH, Kim TY, Kim JY, Kang HJ, Chae IH, Oh BH, Park YB, Kim HS. Identification of a novel role of T cells in postnatal vasculogenesis: characterization of endothelial progenitor cell colonies. *Circulation*. 2007 Oct 9;116(15):1671-82. doi: 10.1161/CIRCULATIONAHA.107.694778. Epub 2007 Oct 1. PMID: 17909106
236. Koo BK, Kim YS, **Park KW**, Yang HM, Kwon DA, Chung JW, Hahn JY, Lee HY, Park JS, Kang HJ, Cho YS, Youn TJ, Chung WY, Chae IH, Choi DJ, Oh BH, Park YB, Kim HS. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. *Lancet*. 2007 Aug 18;370(9587):567-74. doi: 10.1016/S0140-6736(07)61295-1. PMID: 17707751
237. Oh IY, Yoon CH, Hur J, Kim JH, Kim TY, Lee CS, **Park KW**, Chae IH, Oh BH, Park YB, Kim HS. Involvement of E-selectin in recruitment of endothelial progenitor cells and angiogenesis in ischemic muscle. *Blood*. 2007 Dec 1;110(12):3891-9.
238. **Park KW**, Kim YJ, Kim HS. A prominent coronary Thebesian system. *Eur Heart J*. 2007 Oct;28(20):2448
239. Hur J, Yoon CH, Lee CS, Kim TY, Oh IY, **Park KW**, Kim JH, Lee HS, Kang HJ, Chae IH, Oh BH, Park YB, Kim HS. Akt is a key modulator of endothelial progenitor cell trafficking in ischemic muscle. *Stem Cells*. 2007 Jul;25(7):1769-78.
240. Kim HL, **Park KW**, Kwak JJ, Kim YS, Sir JJ, Lee SJ, Lee HY, Chang HJ, Kang HJ, Cho YS, Chung WY, Chae IH, Choi DJ, Kim HS, Oh BH, Park YB, Koo BK. Stent-related cardiac events after non-cardiac surgery: drug-eluting stent vs. bare metal stent. *Int J Cardiol*. 2008 Jan 24;123(3):353-4.
241. **Park KW**, Koo BK, Kim HL, Kim YS, Jo SH, Lee HY, Kang HJ, Cho YS, Chung WY, Yeon TJ, Chae IH, Choi DJ, Kim HS, Oh BH, Park YB. The incidence and predictors of contrast-induced nephropathy in adequately hydrated elderly patients with impaired renal function. *Nephrol Dial Transplant*. 2007 Jun;22(6):1794-5.

242. Lee HY, Chung JW, Youn SW, Kim JY, **Park KW**, Koo BK, Oh BH, Park YB, Chaqour B, Walsh K, Kim HS. Forkhead transcription factor FOXO3a is a negative regulator of angiogenic immediate early gene CYR61, leading to inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia. *Circ Res*. 2007 Feb 16;100(3):372-80. Erratum in: *Circ Res*. 2007 Jul 6;101(1):e1..
243. Hahn JY, Cho HJ, Bae JW, Yuk HS, Kim KI, **Park KW**, Koo BK, Chae IH, Shin CS, Oh BH, Choi YS, Park YB, Kim HS. Beta-catenin overexpression reduces myocardial infarct size through differential effects on cardiomyocytes and cardiac fibroblasts. *J Biol Chem*. 2006 Oct 13;281(41):30979-89.
244. Cho HJ, Kim TY, Cho HJ, **Park KW**, Zhang SY, Kim JH, Kim SH, Hahn JY, Kang HJ, Park YB, Kim HS. The effect of stem cell mobilization by granulocyte-colony stimulating factor on neointimal hyperplasia and endothelial healing after vascular injury with bare-metal versus paclitaxel-eluting stents. *J Am Coll Cardiol*. 2006 Jul 18;48(2):366-74
245. Kang HJ, Lee HY, Na SH, Chang SA, **Park KW**, Kim HK, Kim SY, Chang HJ, Lee W, Kang WJ, Koo BK, Kim YJ, Lee DS, Sohn DW, Han KS, Oh BH, Park YB, Kim HS. Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial. *Circulation*. 2006 Jul 4;114(1 Suppl):I145-51.
246. Lee SP, Youn SW, Cho HJ, Li L, Kim TY, Yook HS, Chung JW, Hur J, Yoon CH, **Park KW**, Oh BH, Park YB, Kim HS. Integrin-linked kinase, a hypoxia-responsive molecule, controls postnatal vasculogenesis by recruitment of endothelial progenitor cells to ischemic tissue. *Circulation*. 2006 Jul 11;114(2):150-9.
247. Suh JW, Koo BK, Zhang SY, **Park KW**, Cho JY, Jang IJ, Lee DS, Sohn DW, Lee MM, Kim HS. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. *CMAJ*. 2006 Jun 6;174(12):1715-22. Erratum in: *CMAJ*. 2006 Jul

- 4;175(1):64.
248. Park JS, Zhang SY, Jo SH, Seo JB, Li L, **Park KW**, Oh BH, Park YB, Kim HS Common adrenergic receptor polymorphisms as novel risk factors for vasospastic angina. *Am Heart J.* 2006 Apr;151(4):864-9.
249. Yoon CH, Hur J, Oh IY, **Park KW**, Kim TY, Shin JH, Kim JH, Lee CS, Chung JK, Park YB, Kim HS. Intercellular adhesion molecule-1 is upregulated in ischemic muscle, which mediates trafficking of endothelial progenitor cells. *Arterioscler Thromb Vasc Biol.* 2006 May;26(5):1066-72.
250. Kim KI, Cho HJ, Hahn JY, Kim TY, **Park KW**, Koo BK, Shin CS, Kim CH, Oh BH, Lee MM, Park YB, Kim HS. Beta-catenin overexpression augments angiogenesis and skeletal muscle regeneration through dual mechanism of vascular endothelial growth factor-mediated endothelial cell proliferation and progenitor cell mobilization. *Arterioscler Thromb Vasc Biol.* 2006 Jan;26(1):91-8.
251. Yoon CH, Hur J, **Park KW**, Kim JH, Lee CS, Oh IY, Kim TY, Cho HJ, Kang HJ, Chae IH, Yang HK, Oh BH, Park YB, Kim HS. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. *Circulation.* 2005 Sep 13;112(11):1618-27.
252. Choi EK, Kim HS, **Park KW**, Kim HK, Cho JW, Lee MM, Park YB, Choi YS. Novel index of coronary collateral development as a useful predictor of clinical outcome in type 2 diabetic patients with coronary artery disease. *Circ J.* 2005 Jul;69(7):786-92.
253. Choi JH, Zhang SY, **Park KW**, Cho YS, Oh BH, Lee MM, Park YB, Kim HS. The association between the T102C polymorphism of the HTR2A serotonin receptor gene and HDL cholesterol level in Koreans. *J Biochem Mol Biol.* 2005 Mar 31;38(2):238-42.
254. Cho HJ, Youn SW, Cheon SI, Kim TY, Hur J, Zhang SY, Lee SP, **Park KW**, Lee MM, Choi YS, Park YB, Kim HS. Regulation of endothelial cell and endothelial progenitor cell survival and vasculogenesis by integrin-linked kinase. *Arterioscler Thromb Vasc Biol.* 2005 Jun;25(6):1154-60.

255. Zhang SY, **Park KW**, Oh S, Cho HJ, Cho HJ, Park JS, Cho YS, Koo BK, Chae IH, Choi DJ, Kim HS, Lee MM. NF-kappaB decoy potentiates the effects of radiation on vascular smooth muscle cells by enhancing apoptosis. *Exp Mol Med*. 2005 Feb 28;37(1):18-26.
256. **Park KW**, Kim DH, You HJ, Sir JJ, Jeon SI, Youn SW, Yang HM, Skurk C, Park YB, Walsh K, Kim HS. Activated forkhead transcription factor inhibits neointimal hyperplasia after angioplasty through induction of p27. *Arterioscler Thromb Vasc Biol*. 2005 Apr;25(4):742-7.
257. Kim HS, Cho HJ, Cho HJ, Park SJ, **Park KW**, Chae IH, Oh BH, Park YB, Lee MM. The essential role of p21 in radiation-induced cell cycle arrest of vascular smooth muscle cell. *J Mol Cell Cardiol*. 2004 Oct;37(4):871-80.
258. Yang HM, Kim HS, **Park KW**, You HJ, Jeon SI, Youn SW, Kim SH, Oh BH, Lee MM, Park YB, Walsh K. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. *Circulation*. 2004 Jul 20;110(3):301-8.
259. Kang HJ, Kim HS, Zhang SY, **Park KW**, Cho HJ, Koo BK, Kim YJ, Soo Lee D, Sohn DW, Han KS, Oh BH, Lee MM, Park YB. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. *Lancet*. 2004 Mar 6;363(9411):751-6.
260. Park SJ, Kim HS, Yang HM, **Park KW**, Youn SW, Jeon SI, Kim DH, Koo BK, Chae IH, Choi DJ, Oh BH, Lee MM, Park YB. Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery. *Arterioscler Thromb Vasc Biol*. 2004 May;24(5):885-91
261. Chae IH, **Park KW**, Kim HS, Oh BH. Nitric oxide-induced apoptosis is mediated by Bax/Bcl-2 gene expression, transition of cytochrome c, and activation of caspase-3 in rat vascular smooth muscle cells. *Clin Chim Acta*. 2004 Mar;341(1-2):83-91.
262. **Park KW**, You KH, Oh S, Chae IH, Kim HS, Oh BH, Lee MM, Park YB. Association of endothelial constitutive nitric oxide synthase gene

- polymorphism with acute coronary syndrome in Koreans. *Heart*. 2004 Mar;90(3):282-5.
263. **Park KW**, Yang HM, Youn SW, Yang HJ, Chae IH, Oh BH, Lee MM, Park YB, Choi YS, Kim HS, Walsh K. Constitutively active glycogen synthase kinase-3beta gene transfer sustains apoptosis, inhibits proliferation of vascular smooth muscle cells, and reduces neointima formation after balloon injury in rats. *Arterioscler Thromb Vasc Biol*. 2003 Aug 1;23(8):1364-9.
264. Kim SH, **Park KW**, Kim YS, Oh S, Chae IH, Kim HS, Kim CH. Effects of acute hyperglycemia on endothelium-dependent vasodilation in patients with diabetes mellitus or impaired glucose metabolism. *Endothelium*. 2003;10(2):65-70.
265. **Park KW**, Choi JH, Chae IH, Cho HJ, Oh S, Kim HS, Lee MM, Park YB, Choi YS. Hepatic lipase C514T polymorphism and its relationship with plasma HDL-C levels and coronary artery disease in Koreans. *J Biochem Mol Biol*. 2003 Mar 31;36(2):237-42.
266. **Park KW**, Choi JH, Kim HK, Oh S, Chae IH, Kim HS, Oh BH, Lee MM, Park YB, Choi YS. The association of cholesteryl ester transfer protein polymorphism with high-density lipoprotein cholesterol and coronary artery disease in Koreans. *Clin Genet*. 2003 Jan;63(1):31-8.

Books:

1. 증례로 배우는 항혈전제 사용 안내서 2024 ISBN: 979-11-5590-261-1 93510
2. Manual of Interventional Cardiology 3rd Edition, 심혈관중재매뉴얼 제3판 대한 심혈관중재학회 편집진. 2016. ISBN 978-89-9657-633-4
3. Update, Manual of Interventional Cardiology 대한심혈관중재학회 편집진. 2022. ISBN: 978-89-965763-4-1
4. Seoul National University Manual of Medicine, 서울대학교병원 내과 집필진. 2012. "ISBN-13 9788970438559
5. Fundamentals of Telemedicine and Telehealth (번역본) 2021. ISBN 979-11-5943-259-0
6. 심혈관질환 가이드북: 심부전 바로알기 2012. ISBN 978-89-97156-07-8

7. 심혈관질환 가이드북: 고지혈증 바로알기 2011. ISBN 978-89-97156-05-4
8. 심혈관질환 가이드북: 부정맥 바로알기 2011. ISBN 978-89-961236-4-4
9. 심혈관질환 가이드북: 고혈압 바로알기 2010. ISBN 978-89-961236-3-7
10. 순환기학 제2판. 최윤식, 이영우 편저. 2010. ISBN: 978-89-3370-581-0
11. SNUH Manual of Cardiovascular Disease, 1st Edition 서울대학교병원 심혈관진료 매뉴얼. 박영배 외 서울대학교병원 순환기내과 교수진 2014 ISBN 978-89-6278-909-6
12. SNUH Manual of Cardiovascular Disease, 2nd Edition 서울대학교병원 심혈관진료 매뉴얼. 오병희 외 서울대학교병원 순환기내과 교수진 2018 ISBN 979-11-5955-316-5
13. SNUH Manual of Cardiovascular Disease, 3rd Edition 서울대학교병원 심혈관진료 매뉴얼. 김효수 외 서울대학교병원 순환기내과 교수진 2024 ISBN 979-11-7068-159-5